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Abstract 
 
Heidi Shaffer, a MultiCare occupational therapist specializing in lymphedema (LE) management, proposed 
the research question of whether bioimpedance spectroscopy (BIS) via the L-Dex (U400 Impedimed) is the most 
reliable, valid, cost-effective and time-efficient assessment tool on the market for measuring LE in comparison to 
circumferential measurements (CM). Shaffer currently uses the L-Dex in practice and hoped to substantiate its 
psychometrics from the literature to promote its clinical usage and potentially obtain consistent insurance coverage. 
A critical appraisal of the literature revealed a strong correlation between BIS and CM, suggesting that both can be 
used reliably and validly in clinical practice. However, BIS can discriminate specifically between intracellular and 
extracellular fluid. Additionally, the research demonstrated that BIS was more sensitive, reproducible, quantifiable, 
time-efficient, user-friendly and generally more widely accepted by clinicians, therapists and patients.  
The knowledge translation implementation consisted of an informative in-service presentation (to 
representatives of Multicare and Impedimed) and a brochure for MultiCare consumers and suggested outcome 
measures for clinicians. A qualitative questionnaire was used to assess the effectiveness of the knowledge translation 
process and to collect future research considerations. The outcomes suggested that there is a need for more rigorous 
studies to support consistent insurance coverage of BIS. Furthermore, our findings have potential to impact 
insurance coverage and to promote improved communication between healthcare professionals. researchers, and 
insurance companies. 
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Executive Summary 
 
Heidi Shaffer, an occupational therapist (OTR/L) and certified lymphedema specialist (CLT-LANA) 
at MultiCare in Gig Harbor, WA collaborated with students in the Master of Science in Occupational Therapy 
(MSOT) program at the University of Puget Sound on a research project focused on lymphedema 
measurements. The purpose of the research was to answer a question proposed by Shaffer which was refined 
by the MSOT students who then produced a knowledge translation portion. The project began in September 
2016 and was completed in May of 2017, taking about 9 months to complete. It was broken down into two 
parts, which consisted of 1) a comprehensive systematic review of the literature to recommend the best 
lymphedema assessments and 2) translate those recommendations into practice by providing this information 
to the right individuals within MultiCare. The student researchers spoke with Shaffer to determine the 
research question and to identify how the question related to her clinic. The question was: “How do 
perometry, bioimpedance spectroscopy (BIS) and circumferential measurements (CM) compare to one 
another based on reliability, validity, cost, and time-efficiency for measuring unilateral lymphedema (LE)? 
The question was inclusive of a majority of the clients seen by lymphedema specialists in their clinics.  
 
The assessments currently used at the Shaffer’s clinic are CM and BIS. Shaffer is disappointed with 
the cost to some clients due to lack of insurance coverage for the L-Dex (bioimpedance). She is also 
unsatisfied with using CM because it takes 15-20 minutes longer than the L-Dex device; hence CM interferes 
with potential treatment time. Her clinical reasoning leads her to believe that the L-Dex provides a more 
accurate and time-efficient measure. It was her hope that the research question posed would back-up this 
clinical reasoning. 
The systematic review was completed as follows: 1) identified assessments that were comparable 
and could be used in a clinical setting; 2) searched five online databases to ensure saturation; 3) documented 
the online search process; 4) determined which assessments would be included and excluded from the review; 
5) applied exclusion and inclusion criteria to include a total of 29 articles in the critical appraisal of the topic 
(CAT) (3 were level I, 5 were level II, 19 were level IV, and 2 were level V studies); analyzed and compared 
the psychometric properties and the clinical utility of each article. Some of the limitations of this systematic 
review include: weak generalizability, difficulty comparing characteristics of assessments, small sample  sizes, 
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and studies involving perometry, which is rarely used in clinics (Robyn Thornburgh, personal  
communication, February 10, 2017). The systematic review demonstrated that BIS is the assessment tool with 
the strongest psychometric properties and would be most likely to meet the specific needs of the lymphedema 
specialists conducting the administration. The strengths of BIS include sensitivity, reliability, time -efficiency 
and potential for long-term cost-savings. 
The next phase of the project was to conduct knowledge translation and begin implementation of the 
research findings into clinical practice. The research was formally presented on two occasions to Maren Fustgaard, 
Vice President of Health Economics and Reimbursement and Sherri Olsen, MultiCare Director of Wound Care. This 
presentation included a review of the research found, an opportunity to report outcome measures, and which next 
steps to take moving forward to encourage insurance coverage of this device. Fustgaard was pleased with our 
research and the content we provided in the presentation. She gave us constructive feedback from the Impedimed 
CEO and other staff members to ensure that our information regarding insurance coverage was communicated in a 
clear, concise, and understandable manner. Olsen was supportive of our research findings and quickly agreed with 
many of our main points. She identified that further research regarding BIS is being conducted by the oncologist 
team at MultiCare. She corroborated Fustgaard’s statement about the importance of billing BIS to demonstrate to 
insurance companies that there is evidence for its use in clinical practice. She asked clarifying questions regarding 
our research, which we were able to answer to her satisfaction. The researchers were asked by both Fustgaard and 
Olsen for a copy of the presentation, brochure, and final research paper for future reference. After viewing our 
presentation and discussing the research, a survey was completed by both Fustgaard and Olsen to measure the 
outcomes of the knowledge translation process. The outcome survey results indicated that our findings had potential 
to be used to encourage utilization of the L-Dex and positively impact regional providers. 
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Final CAT Paper 
 
Focused Question: 
How do perometry, bioimpedance spectroscopy (BIS) and circumferential measurements (CM) compare to one 
another based on reliability, validity, cost, and time-efficiency for measuring unilateral lymphedema (LE)? 
 
Collaborating Occupational Therapy Practitioner: 
Heidi Shaffer OTR/L 
 
Prepared By: 
Jessica Enyeart, Cullyn Foxlee, Divina Ramolete, Connie Wyatt 
 
Chair: 
George Tomlin, PhD, OTR/L, FAOTA 
 
Course Mentor: 
George Tomlin, PhD, OTR/L, FAOTA 
 
Date Review Completed: 
11/15/2016 
 
Clinical Scenario: 
Heidi Shaffer, a MultiCare occupational therapist specializing in LE management, is wondering if BIS via the L - 
Dex (U400 Impedimed) is the most reliable, valid, cost effective and time effective assessment tool on the market 
for measuring LE. In her 12 years of LE clinical experience, she has used an array of assessments, including the 
L-Dex and CM. She is relatively confident that the L-Dex is more accurate and reliable in quantifying changes in 
extracellular fluid (ECF) in the limbs. Additionally, she claims that BIS is faster to administer, therefore 
providing more time in the initial evaluation to treat her clients. This CAT is relevant to Shaffer because she 
wants to substantiate to others (rehabilitation coordinator, MultiCare, insurance companies, etc.) with research 
and evidence-based practice, that BIS is the best instrument on the market for assessing unilateral lymphedema. 
Her primary issue is that most insurance companies do not cover use of the BIS, because CM are built within the 
cost of the initial evaluation. Through this CAT, her aim is to compare lymphedema assessments in order to 
determine if BIS truly is the best instrument, or if other assessments are shown to be better. After critique of the 
literature, she hopes to utilize the evidence in such a way that the L-Dex may in the future be covered by most 
insurances and that BIS may eventually become the gold standard for LE measurement instead of  CM. 
 
Review Process: 
 
Inclusion Criteria: 
LE of arms and legs, secondary LE, unilateral lymphedema, BIS, CM, perometry (including infrared 
optoelectronic volumetry/perometry) and studies done anywhere in the world.  
 
Exclusion Criteria: 
Primary LE, non-human subjects, self-assessment, children, articles older than 1990, head/neck LE, 
studies solely measuring early diagnosis or detection of breast cancer-related lymphedema (BCRL), water 
volumetric measurements (if not compared to CM, BIS or perometry), and tonometry if not within a 
systematic review/meta-analysis. 
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Search Strategy 
 
Categories Key Search Terms 
Patient/Client Population 
lymphedema, lymph*, NOT breast cancer related, NOT BCRL, breast 
cancer, bioimpedance 
Assessment 
measurement, assessment, evaluation, bioimpedance, L-Dex, bioimped*, 
peromet* 
Comparison Circumferential measur*, comparison 
Outcomes Reliab*, valid*, cost, efficien*, accura* 
 
Synonymous Keywords 
 
Keywords Synonym(s) Alternative spelling 
Lymphedema  Lymphoedema 
LE 
Assessment Evaluation 
Measurement 
Measure 
 
Bioimpedance spectroscopy Bioimpedance analysis 
Bioimpedance 
BIA 
BIS 
MFBIA 
SFBIA 
Extracellular fluid Extracellular water ECW 
ECF 
Circumferential 
measurements 
Frustum sign method 
Disk model method 
Anatomical landmarks 
Wrist to axilla measurement 
FSM 
DMM 
CM 
CMAL 
Perometry Optoelectronic volumetry 
Optoelectronic perometry 
Infrared optoelectronic perometry 
Infrared optoelectronic volumetry 
 
 
Databases & Sites Searched 
PubMed – 14 searches 
Primo - 4 searches 
AJOT - 2 searches 
OT Search – 1 search 
PEDro - 1 search 
 
Quality Control/Review Process: 
 
In order to get the most comprehensive searches in the amount of time allotted, our team used five 
databases (listed above) to search the evidence. Our searches began broad, using keywords like 
lymphedema measurements and began to narrow (using specific types of lymphedema measurements) as 
our comprehension of lymphedema assessments increased. Many results from general keywords we used  
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were broad and often not related to the research question. In one search, “comparison” was used to narrow 
and specify a search. Through reading the evidence and consulting the clinician (Heidi Shaffer), our team 
began to comprehend what types of lymphedema measurement tools are used. We further refined our 
search criteria as we began to find data that repeatedly reported positive outcomes for the use of BIS, 
perometry, and CM. We also applied reference tracking and citation tracking methods to some articles  
we’d already found, but those did not yield a high volume of different results due to the extensiveness of 
our database searches. Articles found from reference tracking and citation tracking were only included if 
they were duplicates or had a measurement comparison. Articles with titles indicating that only one form 
of measurement studied were not included because the articles including only one measurement we already 
had provided the background we needed. Our search became saturated with the same articles , at which 
time, we concluded our reference tracking searches. Also, following examination of Perdomo et al. (2014), 
our team is considering changing our exclusion criteria to articles published prior to 2001. 
 
There were 1504 articles found, 1400 rejected, 79 were duplicates with 25 reviewed and placed into our 
critical appraisal of topics table on October 25th, 2016. After further review on November 13th, 2016, 2 
articles from reference checking, and 1 article that came in late from an ILLIAD request (from a database 
search) were added to the table, making 28 the total number of articles placed into the CAT. Many articles 
that were rejected studied only early detection/diagnosis of BCRL and Shaffer was not interested in using 
assessment tools to diagnose or detect LE. Other articles were rejected because they studied treatments for 
LE rather than assessments or measurements of LE. Unfortunately, some articles were excluded because 
they could not be requested via ILLIAD, hence further exploration to obtain these studies is required. 
These potential articles were checked and determined not to fit the criteria for review.  
 
Additional and relatively new studies (Soran et al., 2014; Laidley and Anglin, 2016) were included in the 
CAT on April 12, 2017. They were provided to us in a meeting via Impedimed’s Vice President of Health 
Economics and Reimbursement, Maren Fustgaard. The addition of these articles helps to provide more 
comparison between CM and BIS, highlights subclinical LE and expands on the clinician and patient 
implications regarding BIS. These articles may not have been found or considered within our search 
strategies due to many reasons including: the exclusion criteria of early-detection, limited accessibility to 
specific journals, and cost. Although these studies address early detection, their results and implications 
strengthen and support the literature analyzed in this project. An article was removed on April 17, 2017 
because after close examination of the statistics, it did not appear to have included all information 
necessary to draw conclusions. 
 
Shaffer is the clinician overseeing this research due to her desire to provide better practice for her clients 
and her clinic. All outstanding questions (from team members) concerning Shaffer’s preferences for the 
research question were directed to her via email. Eli Gandour-Rood, a library liaison, aided in search 
strategies and alternative options for searches; one member of our team met with him on Friday, October 
14, 2016. George Tomlin provided our team with essential one-on-four statistical guidance/knowledge, 
search strategies and organizational techniques. Also, all other questions that the team members could not 
find an answer to were directed to George Tomlin. Jessica Enyeart, Cullyn Foxlee, Divina Ramolete, and 
Connie Wyatt put in time to ensure a fluid plan was in place for this critical appraisal. It took an abundance 
of coordination among team members to ensure that data was collected in a structured manner.  
 
Results of Search 
Table 1. Search Strategy of databases. 
Search Terms Date Database Initial 
Hits 
Articles 
Excluded 
Total Selected for 
Review 
(Lymphedema) AND (Measurement) 09/20/16 PEDro 12 12 0 
Lymphedema measurement: 
similar articles via Hidding et al 
09/20/16 PubMed 375 
96 
375 
88 
n/a 
8 
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(2016)      
lymphedema [and] measurement 09/22/16 AJOT 10 10 0 
Lymphedema measurement 
Redone: additional term: comparison 
09/22/16 
10/19/16 
Primo 321 
36 
321 
31 
n/a 
5 
lymphedema measurement (category: 
Master’s thesis) 
09/22/16 OT 
Search 
0 0 0 
Lymphedema AND measurement 09/22/16 PubMed 374 371 3 
lymph* AND measur* 09/22/16 Primo 148 147 1 
Bioimpedance AND cost AND 
lymphedema 
09/27/16 PubMed 4 2 2 
Bioimpedance AND efficiency AND 
lymphedema 
09/27/16 PubMed 0 0 0 
Bioimpedance AND accura* AND 
lymphedema 
09/27/16 PubMed 14 8 6 
Bioimpedance AND reliab* AND 
lymphedema 
09/27/16 PubMed 15 13 2 
Circumferential measur* AND 
lymphedema AND bioimpedance 
09/27/16 PubMed 5 3 2 
Circumferential measur* AND 
lymphedema AND efficien* 
09/27/16 PubMed 2 2 0 
Circumferential AND measurements 
AND lymphedema 
10/17/16 Primo 41 40 1 
Lymphedema AND peromet* AND 
(assessment OR evaluation OR 
measurement) 
09/28/16 PubMed 51 43 8 
((((Lymphedema) AND measurement) 
NOT BCRL) NOT Breast cancer 
related) 
10/06/16 PubMed 287 275 12 
((Lymphedema) AND measurement) 
AND bioelectric impedance 
10/12/16 PubMed 2 2 0 
circumferential AND measurements 
AND lymphedema AND reliability 
10/16/20 
16 
Primo 10 9 1 
Lymphedema AND peromet* 10/17/16 PubMed 68 58 10 
Deltombe, Jamart 10/17/16 Primo 24 23 1 
Lymphedema & water displacement 10/23/16 PubMed 25 23 2 
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volumetry      
Of the 64 articles found, 43 were duplicates. 
Total number of articles used in review from database searches = 21 
 
Table 2. Articles from Impedimed website (https://www.impedimed.com/products/l-dex-u400/) 
Article Date 
Shah et al., (2013) 10/14/16 
Ward et al., (2008) 10/14/16 
Direct correspondence with Catherine Kingsford and Reuben Lawson from Impedimed led us to explore article 
titles and authors shared on their website. They also suggested articles to research via email. Authors and titles 
were then plugged into Primo or Google Scholar to be reviewed. 
Of the 15 articles found, 13 were duplicates from the database searches above. 
Total number of articles used in review from Impedimed website searches = 2 
 
Table 3. Articles from citation tracking.* 
Article Date Database Initial Hits Articles 
Excluded 
Total Selected for 
Review 
Deltombe et al (2007) 10/17/16 PubMed 18 16 2 
Fu et al (2014) 10/18/16 PubMed 6 6 0 
Of the 2 articles found, 2 were duplicates from the database searches above. 
Total number of articles used in review from citation tracking = 0 
*Articles were not further reviewed if the title suggested that only one measurement tool was studied in an article 
because the focus of our research is the comparison of different measurement tools.  
 
Table 4. Articles from reference tracking.* 
Article Date Articles Referenced Articles Excluded Total Selected for 
Review 
Seward et al., (2016) 10/14/16 30 25 5 
Smoot et al., (2011) 
(not used in CAT) 
10/15/16 25 21 4 
York et al., (2008) [This 
should stay because we used 
it for reference tracking] 
10/18/16 17 15 2 
Czerniec et al., (2010) 10/20/16 28 21 7 
Perdomo et al., (2014) 10/20/16 82 77 5 
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Fu et al., (2013) 10/20/16 29 27 2 
Adriaenssens et al., (2013) 10/28/16 38 27 11 
Hayes et al., (2008) 10/28/16 25 22 3 
Bilir et al., (2012) 11/11/16 43 40 3 
Hidding et al., (2014) 11/11/16 70 53 17 
Jain et al., (2010) 11/13/16 29 24 5 
Of the 64 articles selected for review, 59 were duplicates from the database searches above. 
Three articles were eliminated due to not meeting inclusion criteria. 
Total number of articles used in review from reference tracking = 2 
*Dups = Duplicates of articles used in CAT 
*Articles were not further reviewed if the title suggested that only one measurement tool was studied in an article 
because the focus of our research is the comparison of different measurement tools.  
 
Total number of articles used in review from database searches = 21 
Total number of articles used in review from Impedimed website = 4 
Total number of articles used in review from citation tracking = 0 
Total number of articles used in review from reference tracking = 2 
Total number of articles used in review from UPS Master’s Thesis = 0  
Total number of articles used in review from Impedimed Vice President = 2 
Total number of articles used in CAT = 29 
 
Summary of Study Designs of Articles Selected for the CAT Table 
Pyramid Side Study Design/Methodology of Selected Articles Articles Selected 
 
 
 
Outcome 
 
2 Systematic Reviews of Related Outcome Studies 
0 Individual Quasi-Experimental Studies 
5 Case-Control Studies 
0 One Group Pre-Post Studies 
 
 
 
7 
 
 
 
Descriptive 
 
1 Systematic Reviews of Related Descriptive Studies 
19 Association, Correlational Studies 
2 Multiple Case Studies (Series), Normative Studies 
0 Individual Case Studies 
 
 
 
22 
AOTA Levels 
I- 3 articles 
II- 5 articles 
IV- 19 articles 
V- 2 articles 
 
 
Total Articles: 29 
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Systematic Reviews 
 
Author, Year 
 
Study 
Objectives 
Study 
Design, 
Level of 
Evidence 
 
# of papers, inclusion/exclusion 
criteria 
 
Interventions & 
Outcome Measures 
 
Summary of Results 
 
Limitations 
Hidding Determine Systematic 27 studies Quality Assessment of BIS is ideal for detection in earlier stages of LE is defined 
et al., which LE Review The following measurements were Diagnostic Accuracy Studies- LE because it is sensitive enough to identify a differently by 
(2016) measurements D1 compared more than once: BIS: 3, 2 (QUADAS-2): Used to change at first stage LE. Variations in the 2nd different studies. 
PT have the best Level I MFBIA: 3, WD: 10, CM: 12, OP: 3, document concerns regarding stage of LE can be identified by other physical Most studies were 
 reliability &  Tonometry: 3, Self-report: 2 applicability and amount of measurements. OP, WD, & CMs all have high not blinded studies, 
 validity for a  The following were only seen once: bias. Four components of IAR. WD has a high concurrent validity w/ which might have 
 given stage of  Moisture Measure: 1, Goniometry: 1 methods are scored w/ the BIS & CMs. Studies reviewed support these eliminated bias. 
 LE  Inclusion criteria: Measurements following method: assessments of LE as effective tools for Participant 
   performed X2, comparisons of Likely applicable or bias measuring LE. exclusion/inclusion 
   assessments unlikely= “+”  criteria not always 
   Studies: Case Probably applicable or bias  clear. 
   control/prognostic/cross-sectional possible= “?”   
   Language of study: Probably not applicable or bias   
   English/Dutch/German/French very possible= “-“   
   Quality: The Quality Assessment of Reliability: (95% confidence   
   Diagnostic Accuracy (QUADAS-2) for all the following)   
   Exclusion criteria: X-ray CM (tape measure) for upper   
   absorptiometry, tomography*, & extremity:   
   goniometry*, patient-reported IAR: ICC=0.99 CI: 0.99-0.99   
   questionnaires, CG sig younger M IER: ICC=0.98 CI: 0.98-0.98   
   age than affected population BIS IAR: 0.88-0.99   
   *These assessments were included, OP for upper extremity:  IAR:   
   but never w/o being compared to at ICC=0.99 CI: 0.97-1.00   
   least one other assessment Volumeter for upper extremity:   
    IAR/IER: ICC=0.99 CI: 0.99-   
    0.99   
    Concurrent validity:   
    (WD used for comparison)   
    WD to CM range: 0.80-0.99   
Perdomo et al., Identify Systematic 51 papers: 13 CM, 9 WD, 3 I: CM, WD, tonometry, BIS, Edge scores of importance: 4 = highly Potential to be more 
(2014) RO specific Review tonometry, 10 BIS, 13 OP, 3 self- OP, & self-report recommended, good psychometric properties extensive & 
 assessment O1 report; 2001-2012; 15 databases;  & good clinical utility, has been used in BC informative; doesn’t 
 techniques Level I Inclusion: UE, secondary LE, adult, OM: Breast Cancer EDGE research; 2A = Unable to recommend, explicitly specify 
 recommended EDGE form F, breast neoplasm; Exclusion: form based on IAR, IER, CC, insufficient info to support tool, although studies used in 
 for use in used to grade Languages other than English, sensitivity, specificity (ROC measure has been used in BC research; review 
 clinical all studies primary LE, lower extremity, curve), SRD, SEM, CI, LAA, CM, WD & BIS scored an EDGE 4 while  
 practice to  venous, male, MRI,  tonometry, OP, & self-report scored an EDGE  
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 measure UE 
secondary LE 
in BCS 
 lymphoscintography, CT scan, 
ultrasound, Doppler 
 2A  
Seward et al., Analyze Comprehensive 23 studies: SFBIA vs CM (3), I: SFBIA, CM, MFBIA, BIS, BIS is an effective tool for well-established No grading tool used, 
(2016) JSO advantages, Review SFBIA vs MFBIA (3), BIS vs OP WD BCRL. SFBIA less accurate than MFBIA; BIS methods section is 
 disadvantages O1 (6), MFBIA vs CM/WD (7), BIS vs  use combined w/ volumetric techniques could one sentence, tables 
 & results of Level I 2 or more other techniques (4). OM: Psychometrics (specifics yield max benefits for all patients. One study describing studies 
 studies w/  1992-2015. Inclusion: Studies w/ not stated) showed that BIS can detect edema as early as need more info. 
 evidence base  direct analysis of BIS related to  10-months sooner than CM. 100% sensitivity  
 for detection  BCRL. Exclusion: not stated.  & 98% specificity. Other studies show no  
 & measure of    statistical difference seen b/w LG & CG using  
 BCRL using    BIS. BIS reported false negative rate of 27% in  
 BIS    one study. Results vary highly. BIS results are  
     best read as resistance ratios & are less  
     accurate when converted to volume.  
 
Bioimpedance Spectroscopy and Optoelectronic Perometry compared to one another (* indicates studies where CM was also include d) 
Author, 
Year 
 
Study Objectives 
Study Design, 
Level of 
Evidence 
 
Assessments 
 
Psychometrics 
Population, 
Setting 
 
Summary of Results 
 
Limitations 
Bundren et To determine the best Correlational OP & BIS (L-Dex Paired t-tests used for 612 women (M age These results show the need for True and false 
al., (2015) method of detecting D2 U400) comparison = 55 y.o) pre-operative measurements to positive & true and 
BCRT LE after axillary Level IV LV measured pre BC Using pre-operative undergoing surgery be taken and used for baseline false negative values 
 surgery  axillary surgery and measurements as baseline: OP for BC were measures prior to treatment. were not reported 
   post for at least 6 detected 52 patients w/ LE by 6 recruited from 7 This will allow for clearer clearly 
   months, analysis for months, when using 1-month centres across the indications for the effects of This is only the first 
   this current report post measurements as baseline, UK between July treatments on the development analysis of what will 
   involved comparison OP detected 43 patients w/ LE 2010 and May of LE. This is contrary to what be a five year follow- 
   of the baseline (pre) by 6 months but 12 were 2014. 42 % had is currently occurring up with patients 
   and 1-month post- different patients so there was undergone internationally, with medical when complete, so 
   surgery only 31 in agreement mastectomy insurance refusing to pay for the final data will be 
    Using pre-operative  pre-operative BIS more definitive, 
    measurements as baseline: BIS  measurements, saying that 1-  
    detected 106 patients w/ LE by 6  month post-operative measures  
    months, when using 1-month  are sufficient.  
    post measurements as baseline,  This current data comparing  
    BIS detected 67 patients w/ LE  pre-operative w/ 1-month post-  
    by 6 months, there were 53 in  operative OP and BIS  
    agreement  measurements have shown  
    Pre-operative BIS score mean  significant difference between  
    was -0.16 (range -22.10, 26.90),  these 2 time points.  
    1-month post BIS score mean  Both OP and BIS appear to  
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    was 2.86 (range -17.50, 53.40), p  indicate that there is a degree  
< 0.005 of over and under diagnosis of 
Pre-operative OP score mean LE if 1-month post-operative 
was 4.43 ml (range -514, 580), measurements are used rather 
1-month post OP score mean than pre-operative 
was 33.22 ml (range -493, 623) p  
< 0.005  
Moderate correlation between  
OP and BIS at 3 months (r =  
0.40) and 6 months (r = 0.60)  
Sensitivity = 73 % (95% CI:  
0.59-0.84)  
Specificity = 84 %(95% CI: 0.80  
-0.87  
*Czerniec et To compare the Correlational VAS-Self-report CI: 95% for the following English speaking Physical methods: high OP could not 
al., (2010) CI physical methods of D2 BIS data: women w/ BC tx agreement w/ each other measure the entire 
 LE (BIS, OP, & Level IV OP Reliability of Physical induced unilateral Physical measurements: length of arm on 11 
 truncated cone)  Truncated cone Measures on Affected arm LE: 33 moderate agreement w/ VAS participants w/ LE & 
   method Extremity: CG: Women w/o Physical measurements had 7 w/o. Not a blind 
    OP: BC or LE or both high IAR reliability & study, so it was 
    LG ICC: 1.00 (CI: 0.99-1.00) medical history of IER reliability. known who had LE 
    CG ICC: 1.00 (CI: 0.99-1.00) either condition: 18 BIS: higher IER than truncated & who did not. This 
    BIS: Exclusion: cone measurement; is the more could have caused 
    LG ICC: 0.95 (CI: 0.90-0.98) Pregnant women sensitive measure when bias in the 
    CG ICC: 0.81 (CI: 0.56-0.93) &/or pacemaker (or compared to OP and truncated measurements 
    Truncated cone CM: other built-in cone measurements in reported from the 
    LG ICC: 0.98 (CI: 0.96-0.99) device) detecting differences researchers since 
    CG ICC: 0.98 (CI: 0.95-0.99) Participant unilaterally they knew who had 
    Correlation b/w Physical recruitment Physical measures cannot LE and thus knew 
    Measures & Other physical involved replace each other for a single from whom a change 
    measures: advertisements & patient; not interchangeable would more likely be 
    truncated cone v. OP: media releases. Truncated cone method seen. 
    Total limb:  underestimated volume  
    CC=0.98  compared to OP  
    Limb difference: CC=0.99    
    Inter-limb ration: CC=0.98    
    BIS v. truncated cone:    
    CC=0.89    
    BIS v. OP:    
    CC=0.92    
    BIS (.99) had higher IER than    
    CM (.98)    
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Czerniec et 
al., (2009) 
SCC 
To determine if BIS 
can detect localized 
LE of arm & compare 
BIS measures w/ OP 
Correlational 
D2 
Level IV 
OP  (peroplus 
software) & BIS (Imp 
RSM version 1.12.0 & 
Bioimp Version 2.25 
Impedimed Ltd) 
Measured up arm 
starting at ulnar styloid 
process - 0-10cm, 10- 
20cm, 20-30cm, 30- 
40cm 
LCC: (rc = 0.86) CC among arm 
segments varied (rc = 0.46 to rc 
= 0.78) 
LAA: Bias ranged from 10% to 
16% among segments. Bias was 
positive toward BIS on all 4 
segments 
ANOVA: sig difference b/w 
groups (F(1, 38) = 9.256; p 
=.004), b/w BIS & OP (F(1, 38) 
= 11.552; p =.002), sig 
interaction b/w groups & 
assessments (F = 8.926; p =.005) 
As expected, both instruments 
showed results when 
lymphedema was present. BIS 
was also more sensitive in 
detecting lymphedema when 
compared to OP. 
29 F w/ mild to 
severe upper limb 
LE (M age: 60); 11 
F w/ no hx of LE 
(M age: 53.5). 
Inclusion: 
understand English; 
Exclusion: 
Pacemakers, inbuilt 
stimulator, 
pregnancy 
BIS is able to detect localized 
changes with a higher degree of 
sensitivity than total LV 
measures; this is because BIS is 
designed to differentiate b/w 
ECF & other fluids which 
allows BIS to detect localized 
LE more readily than OP. BIS 
can detect LE before it 
manifests as a total LV change. 
Segmental BIS is not 
recommended, but rather whole 
arm measures. 
4 F weren’t 
measured @ 30- 
40cm due to arm 
length/trunk shape; 
cut-off values for 
BIS & OP for whole 
arm may not be 
applicable to 
individual segments; 
normative data for 
limb segments need 
to be established; no 
preoperative data. 
No direction of 
differences reported. 
Dylke et al., 
(2016) AO 
Determine which 
normatively 
determined &/or 
commonly used 
diagnostic thresholds 
are optimal for 
diagnosis of LE when 
compared to 
lymphoscintigraphy 
Correlational 
D2 
Level IV 
OP (Peromerter, 
1000M Juzo) & BIS 
(SBF7, Impedimed 
Ltd.) & 
Lymphoscintigraphy 
ANOVA & ICC 
Limb ratio determined by 
comparison of A & U arms. 
IAR of dermal backflow scoring 
= ICC: 0.957, 95% CI 0.885- 
0.984 
M OP inter-LV difference 
increased consistent with dermal 
backflow score (f = 88.32, p < 
0.001) 
Diagnosis of LE with BIS & OP 
sig better compared to 
lymphoscintigraphy (x
2 
= 25.8- 
63.8, p < 0.05) Specificity range 
67%-94%. Sensitivity range = 
92-100%. 
68 F recruited 
through open 
advertising. 68 
women previously 
treated for LE 
(LG), 13 without 
BC or LE (CG), 6 
with hx of BC but 
no LE (BC group) 
IAR of dermal backflow 
scoring was found to be 
excellent. 
58% of women in LE group 
had severe dermal backflow 
OP LV increased with dermal 
backflow score increase 
Diagnosis of LE by OP & BIS 
was excellent compared to 
Lymphoscintigraphy. 
Lacking detail about 
participant’s medical 
hx, demographics & 
presentation. 
Almost ½ of the LE 
groups data could 
not be used due to 
excess dermal 
backflow levels 
Jain et al., 
(2010) (L) 
1.Establish the IER & 
IAR of BIS 
Correlational 
D2 
BIS & OP Raw data values for both BIS & 
OP were converted into ratios of 
Convenience 
sample of 10 F 
Sig differences b/w BIS values 
of A & U arms based on 
Study was limited to 
10 participants due 
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 2.Establish Level IV  A to U limbs for comparison. volunteers recruited measurements by R1 & T1 & to BIS being 
concurrent validity of  Paired t test used to compare through Nat. BC T2 of R2 considered 
BIS compared to OP  volumes obtained by both Support OP identified sig volume “investigational” at 
when determining  measures. Linear correlations Organization. differences b/w A & U arms. the time 
ratios of affected  b/w BIS ratios for A & U arms Ages 49-67 y.o IER b/w R1 & R2 was very Small sample size 
limbs to unaffected  calculated for two trials of rater 8 Caucasian, 1 good BMI for patients 
limbs  2(R2) & b/w measurements of African America, 1 IAR for R2 was very good varied widely 
  rater 1(R1) & first trial (T1) of Hispanic ICC for raw data of A & U BIS is unable to 
  R2 to determine IER & IAR. All were right hand arms within & b/w raters was restrict 
  IER & IAR reliabilities of raw dominant, 4 with good. measurements to a 
  BIS scores examined by ICC. pathology on right  single segment of the 
  Concurrent validity against OP side OP & BIS ratios were inversely limb whereas OP & 
  determined by calculating linear  & sig correlated CM can 
  correlations b/w A & U ratios for  Data indicates that BIS is able  
  OP & BIS.  to produce reliable IER & IAR  
  IER agreement b/w R1 & R2, r  measurements & there is  
  =0.987, p < 0.005 with BIS  concurrent validity b/w BIS &  
  IAR for R2, r = 0.993, p < 0.005  OP  
  ICC for raw data of A & U arms    
  ranged from 0.969 to 0.996    
  within & b/w raters.    
  OP ratios were inversely & sig    
  correlated with BIS ratios range    
  r = -0.89 to -0.90 , p <0.005    
Moseley, To determine Correlational OP & MFBIA; Pearson correlation analysis: 33 (28 F, 5 M) w/ MFBIA is more accurate for lack of statistics, old 
Piller & effectiveness of OP D2 baseline taken prior to OP & MFBIA: secondary LE (M limb fluid change. OP is more article, no control 
Carati (2002) compared w/ MFBIA Level IV 3 week home LE r = 0.611 (p<0.001); age: 59) Inclusion: accurate determination of total group, MFBIA taken 
(L)   program & measures r = 0.495 (p<0.004) for changes ability to stand for LV change. Both are equally during standing 
   taken each week & 1 measured by both; 2 mins, to abduct valid in measuring leg volume  
   month post tx. MFBIA: internal consistency w/ hips, to hold leg changes. Both OP & BIS are  
    change in ECF (r = 0.427, p horizontally for 1 non-invasive, easy & quick  
    <0.001). min. Exclusion: not methods to assess secondary  
     listed lymphedema.  
*Ridner et 
al., (2007) 
(L) 
To examine 
relationship b/w CM, 
OP, & BIS 
Correlational 
D2 
Level IV 
CM via tape measure 
wrist to axilla (25min) 
OP via perometer 
1 visit, 60-90-minute data 
collection session; 3 
measurements for each 
N=25 
LG: 11 
CG: 14 
Strong correlations b/w BIS 
methods; Strong correlations 
b/w CM & OP 
Participants unclear; 
male/female? 
Cannot generalize 
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   350S (5 min) arm/assessment→ averaged  Less strong correlations due to small sample 
BIS via CM & OP: r = 0.877 Inclusion: CG→ expected b/w BIS, CM, & OP; size, participants 
LYM & EIS (6 min) CM & EIS: r = 0.708 age 18+, no history further validate different measured only one 
LYM: single CM & LYM: r = 0.727 of lymphedema, measurement approaches; time & menstrual 
frequency provides LYM & EIS: r = 0.987 capable of Recommend consideration of cycle status not 
difference in fluid b/w  informed consent time when choosing an LE considered which 
affected & unaffected  LG: 18+ y.o, assessment may affect lymph 
limbs  diagnosis of  ratios 
EIS: multi-frequency  unilateral   
  lymphedema, self-  Different data 
  reported history of  collectors for CM 
  lymphedema or  Dominant vs. non- 
  swelling prior to tx  dominant limb ratios 
  Exclusion:  not included; unclear 
  pregnancy,  what impact this may 
  pacemaker,  have. 
  implants, allergies   
  to electrodes   
Ward et al., To assess agreement Correlational Both arms of each OP calculated via Peroplus Women from BIS & OP strongly correlated; CG younger & 
(2009) LRB b/w BIS indices & D2 participant measured. software, relationships assessed Breast Cancer BIS can be converted to weighed less than 
 inter-limb volume Level IV BIS Indices: (SFB7; by correlation & LAA analysis Research Group volume measurement LG group; did not 
 differences via OP  impedimed) → LG: LG: 45 women w/ Generally good LAA except control for these 
   impedance ratio of Impedance ratio: 1.273+/- 0.245 unilateral for covariates 
   extracellular fluid only L-dex: 25.6+/-24.9 lymphedema classification; methods not LAA are unclear; 
   Single frequency Arm 40cm segment volume ml: CG: 21 women w/ interchangeable but can be data needed to be 
   impedance monitor Affected: 2572+/-757 no history of used independently scaled 0-100; article 
   (model XCA; Unaffected: 2095+/- 586 lymphedema Lower validity w/ OP would states both poor & 
   impedimed) → L-dex CG: Women from not detect lymph close to axilla generally good LAA 
   score (conversion of Impedance ratio: 1.016+/- 0.046 Breast Cancer BIS detected greater difference  
   SFB7) L-dex:1.4+/-5.9 Research Group when arm lymph differences  
   OP: (Perometer 350S) Arm 40cm segment volume: Inclusion: were larger vs. OP; BIS  
   → 40cm volume Dominant: 1964+/-478 Unilateral reflected specificity &  
   % of unaffected arm Non dominant: 1924+/-502 lymphedema as a sensitivity to detect changes in  
   volume corrected r = 0.926 b/w impedance ratio, consequence of tx ECF  
   3.6% for limb L-dex score & OP of both groups for breast cancer Recommends BIS use for early  
   dominance (total limb r = 0.919 b/w impedance ratio, Exclusion: stage lymphedema when  
   volume) L-dex score & OP of LG group Pacemaker, changes are predominantly in  
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     pregnant extracellular fluid 
Both suitable, rapid to perform 
& noninvasive to pt; BIS 
cheaper 
 
 
Bioimpedance Spectroscopy compared to Circumferential Measurements and/or Water Displacement 
 
Author, Year 
 
Study Objectives 
Study Design, 
Level of 
Evidence 
 
Assessments 
 
Psychometrics 
 
Population, Setting 
 
Summary of Results 
 
Limitations 
Cornish et al., Investigated Pre-existing CM & MFBIA LAA: University of Queensland: MFBIA & CM measures No sensitivity or 
(1996) BCRT application of groups (Swept frequency CG: 20 F w/ no hx of LE different physiological specificity 
 MFBIA to monitor comparison bioimpedance 2)– 3.1% bias (university staff) (M age: quantities; not scalar psychometrics; old 
 LE volume in UE O3 Daily schedule w/ Patient: 40); 20 F w/ grade 2 quantities of each other. article implies that 
 limbs diagnosed w/ Level II compression 15-21% bias unilateral LE (M age: 60). MFBIA, which measures newer statistical 
 LE following BC  therapy/bandaging Mann-Whitney 2-sample test: Inclusion Criteria: age 18+ actual ECW, has greater options now & 
 surgery  & massage for 4 MFBIA: CI: -3.3%  sensitivity & precision in upgraded BIA 
   wks. Daily MFBIA <ECW<10.5%. CM:  detecting changes than an equipment now; no 
   & CM measures -7.5%<Volume ratio< 12.5%.  assessment tool which baseline measures 
   taken during 1st 4   measure total LV (i.e., CM).  
   wks.   MFBIA also measures  
      ICW. MFBIA has been  
      shown to be more sensitive  
      to lower levels of LE &  
      monitoring changes to tx  
      response. MFBIA offers a  
      technique that is more  
      discriminatory, sensitive,  
      reproducible, and  
      quantifiable than CM.  
Fu et al., To estimate Pre-existing BIA & CM (Test- Strong agreement among all 3 60 F w/ no hx of LE (CG) BIA using L-Dex is a highly Characteristic 
(2012) (L) reliability, groups Retest 3x @ 5 min measures: ICC: CG & at-risk (M age: 36.5); 42 F w/ reliable method to assess differences among 
 sensitivity, comparison intervals). groups (ICC: 0.99 (CI: 0.99- BCRL (M age: 58); 150 F LE among healthy women CG, at-risk & LG; 
 specificity & AUC O3 BIA Specifics à 0.99)); Fair agreement among BCS @ risk for LE (M age: & BCS at-risk for LE; no baseline BIA 
 for cross sectional Level II Imp XCA® - all 3 measures for LG: ICC: 55.8); Inclusion: English, reliability was acceptable measure prior to 
 assessment of BIA  Impedimed; (ICC: 0.69 (CI: 0.58-0.82)). age 18+; Exclusion: Bilateral for survivors with LE. cancer surgery; no 
 to detect arm LE &  >30kHz; L-Dex Sensitivity & Specificity: breast disease, recurrent There was a sig correlation follow-up measures 
 relationship b/w  Ratio used; Discriminating b/w CG & LG; cancer, artificial b/w BIA by Imp XCA(R) &  
 BIA & CM  electrodes placed on AUC of 0.975 (CI: 0.951-0.999; limb/knee/hip, & CM, which indicates that  
   dorsum of R & L p<0.001) Discriminating b/w at- kidney/heart failure. (BIA both can be used to measure  
   wrists adjacent to risk & LG: AUC of 0.941 (CI: not accurate under these LE in clinical practice.  
   ulnar styloid process 0.907-0.976; p<0.001). Using conditions) All participants Also, the BIA by Imp  
    L-Dex ratio >+10 recruited in NYC XCA(R) is time efficient  
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    discriminating b/w CG & LG metropolitan cancer center & (<5 mins to administer) &  
yielded AUC of 0.86 (CI: 0.76- NYC metropolitan requires no certification to 
0.91); sensitivity=0.66 (CI: community. operate & L-Dex ratios take 
0.51-0.79); specificity=0.99 (CI:  into consideration inherent 
0.93-0.99); discriminating b/w  differences b/w dominant & 
at-risk & LG yielded AUC of  non-dominant limbs. 
0.81 (CI: 0.76-0.91)   
sensitivity=0.66 (CI: 0.51-0.79);   
specificity=0.95 (CI: 0.90-0.98);   
BIA & CM (r = 0.44; CI: 0.16-   
0.66; p <0.01)   
Ward (2006) Present evidence Opinion Paper BIA, CM & WD Variation for repeat This is an opinion paper and BIA is found to be faster, BIA is still 
LRB that BIA is a D2  measurements: BIA does not include any details more consistent, better considered novel 
 sensitive & accurate Level V  0.60(15.4%), CM 2.1(35%) of the subjects from the accepted by clinicians,  
 instrument suitable   Low inter-rater variability in studies referenced other than therapists & patients, than Does not provide 
 for measuring LE   BIA that they were women with WD or CM. It is portable, information about 
    Speed to administer: BIA = 1 LE and had undergone relatively inexpensive & settings or 
    min, CM = 7 min surgery for BC at some can be administered by non- populations studied 
    Sensitivities: CM = 35%, BIA point. specialist personnel. by the articles the 
    = 65%.   information is 
    Corresponding specificities:   gathered from 
    CM = 88.5%, BIA = 76.9%    
 
Bioimpedance compared with itself 
 
Author, Year 
 
Study Objectives 
Study Design, 
Level of 
Evidence 
 
Assessments 
 
Psychometrics 
 
Population, Setting 
 
Summary of Results 
 
Limitations 
Shah et al. To examine if BIS Pre-existing BIS (L-Dex U400) tx interventions outcome N=50 participants data BIS found to be valid in Did not describe 
(2013) (L) can detect changes groups Scores monitored measures from 3 centers that detecting early onset specifics of BCRL tx 
 in lymphedema comparison baselineàpost- BCRL tx: M change L-Dex used L-Dex U400 lymphedema after BC surgery or W/o tx. 
 following tx for O3 surgery score baseline to 1st post- BCRLtx: 13 & monitored reduction in L- Retrospective review 
 BCRL Level II  surgery = 8.1+/-7.3 CG W/o tx: 37 Dex scores post-BCRL tx subject to bias of 
    W/o tx:   analysis. 
    M change L-Dex score baseline Subset group N=32 of  Lacks long-term 
    to 1st post-surgery = 1.6+/-5.8 50 w/elevated L-Dex  follow up & L-Dex 
    Sig. reduction in M L-Dex score scores post-surgery  scores; definitive 
    p=.001 following BCRL tx (- BCRL tx:11 of 32  conclusions due to 
    5.8) vs. CG (0.1) For Subset W/o tx: 21 of 32  small sample size. 
    group Inclusion: diagnosis of  No standardized time 
    Sig. reduction p=.005 in M L- BC, 18+ y.o,  points tracked 
    Dex score from 1st post tx to underwent  measurements. 
    last tx when comparing BCRL lumpectomy or   
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    tx (-4.3+/- 5.5) & CG (.0.1+/- 
4.25) 
mastectomy w/SLN or 
ALND, pre-surgical 
(within 180 days of 
surgery) & post- 
surgical L-Dex scores. 
Exclusion: implantable 
devices, bilateral 
lymphedema, 
pregnancy, renal/heart 
failure 
  
Warren et al., To establish the Normative BIS Flow impedance from affected LG: 15 M: 55.2 y.o BIS yields negative different Bilateral LE can 
(2007) APS reliability & D3 No comparison upper extremity or lower Range: 39-72 y.o average ratios for LG & CG. produce inaccurate 
 validity of BIS as Level: IV  extremity, to unaffected upper Diagnoses: This difference b/w LG & CG results when BIS is 
 an assessment of   extremity or lower extremity Upper extremity LE: 9 indicates BIS can be used to used. One participant 
 LE in a population   respectively: Unilateral lower assess changes in swelling of was included who had 
 including lower   LG: extremity LE: 4 limbs with lymphedema. It was bilateral LE. 
 extremity, upper   Average: 0.9 Bilateral congenital noted that in some bilateral Some participants w/ 
 extremity &   Range: 0.67-1.01 LE: 2 lower extremity patients w/ LE were w/in the 
 congenital LE w/   CG: LE symptoms specific complications BIS did range of the CG flow 
 mild to severe LE.   Average: 0.99 reported: not appear to be a good impedance ratio. 
    Range: 0.95-1.02 M: 8.5 y.o diagnostic tool Reasons for this are 
     Range: 3 months-40  given as mild LE & a 
     y.o  body-contouring 
     CG: 7  procedure. 
     M: 26.9 y.o  Small study w/ 
     Range: 25-34 y.o  participants only 
     Setting: Medical  recruited from one 
     Center  hospital. 
 
Optoelectronic Perometry compared to Circumferential Measure and/or Water Displacement 
 
Author, Year 
 
Study Objectives 
Study Design, 
Level of 
Evidence 
 
Assessments 
 
Psychometrics 
 
Population, Setting 
 
Summary of Results 
 
Limitations 
Adriasenssens To compare mobile Correlational OP (1000M, Pero- OP CG Mean Volume: Setting: Breast Clinic When comparing OP, WD & 8 BCS without LE 
et al., (2013) infrared D2 Sustem GmbH, dominant arm: 1771.7ml +/- of the Universitair CM (all 3 methods) for the were included in the 
(L) optoelectronic Level IV Wupertal, Germany; 338ml Ziekenhuis Brussel edematous arm (LG) and the LE group. 
 volumetry w/ WD  Peroplus Software Non-dominant arm: 1731.4ml (UZB) dominant arm (CG), the  
 and CM  TM) +/- 324.4ml CG: 31 (80.6% frustrum and DMM gave the  
   WD: plexiglass OP LG Mean Volume: females) highest volume estimation. WD  
   water tank edematous arm: 2504ml +/- LG: 49 females & single frustrum gave the  
   9x7x75cm 701.2ml Inclusion: No shoulder lowest volume estimation, while  
   CM: frustrum, Non-edematous arm: 1996.4ml mobility restrictions, OP was in b/w.  
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   single frustrum & 
DMM (every 4cm) 
+/- 426.6ml 
Three repeated measures w/ 
OP w/ same PT: 
CG: Dominant arm ICC: 0.998 
Non-dominant arm ICC: 0.997 
LG: Edematous arm ICC: 0.999 
Non-Edematous arm ICC: 0.998 
 
: 
no open wounds at the 
upper limb, able to 
stand w/o support 
When comparing OP, WD & 
CM (all 3 methods) for the non- 
edematous arm (LG) and non- 
dominant arm (CG), the 
frustrum and DMM gave the 
highest volume estimation. WD 
gave the lowest volume 
estimation while single frustum 
and OP were in b/w. 
Due to its reproducibility, ease 
of use, and arm volume 
measurements, which are not at 
the extreme high or low of 
multiple methods, OP could be 
beneficial. 
 
Deltombe et 
al., (2007) (L) 
To compare IAR, 
IER, RD & to 
determine LAA of 
lymphedema from 
CM, WD, IOV of 
upper limbs 
Correlational 
D2 
Level IV 
CM via FSM or 
DMM calculation 
WD 
IOV 
PT1 performed measure 2x; 
IAR PT2 & PT3 performed 
each measure once; IER; 
analyzed via SPSS w/ ICC 95% 
CI, M, SD, LAA 
FSM: 
IAR: 0.96 
IER: 0.94 
DMM, WD, IOV: 
IAR: 0.99 
IER: 0.99 
IAR Differences 
FSM: (3.2+/-4.6%) 
WD: (2.9+/- 2.9%) 
DMM: (1.9+/-2.9%) 
IOV: (1.5 +/-1.4%) 
IER Differences 
IOV: (1.7+/-1.6%) 
FSM: (4.8+/-3.2%) 
WD: (4.5+/-3.8%) 
DMM: (3.1+/-2.2%) 
30 women volunteers 
age 46-79 
Included: clinical 
diagnosis of chronic 
arm lymphedema 
secondary to unilateral 
breast cancer tx; from 
rehab program in 
department; total/ 
partial mastectomy 
Excluded: 
neoplastic process, 
bilateral surgery, 
recent lymphangitis, 
brachial plexitis, 
validity of assessments 
IOV & CM via DMM highest 
reliability 
WD had lowest IAR & IER 
IAR of CM via DMM sig better 
than FSM & WD 
IAR RD were lower than IER 
RD for CM & WD; no 
difference b/w IOV 
Time consuming: 1 
hour to complete WD 
measurements. 
Difficulty of 
positioning upper 
limb vertically in 
WD. 
Possible errors due to 
water loss. 
Cannot generalize 
due to 3PTs 
measuring & 
performing 
calculating CM; 
small sample size 
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Mayrovitz et Determine how LV Correlational CM & OP (Pero- Legs: Automated volume 62 consecutive No sig diff b/w the two Did not include 
al., (2000) measured by D2 system, Perometer 7.16(0.17), tape measure patients referred to measurements. OP had slightly details of etiology, 
ASWC automatic method Level IV model 350S) volume 6.9(0.17), % difference outpatient LE center, sig higher M volume estimates disease duration, type 
 compares to   4.14(0.54), Correlation 62 measured pre-tx, 30 overall or other tx details. 
 standard tape   coefficient 0.9777 measured post. 184 Close relationship exists b/w LV May be harder to 
 measurements   Arms: Automated volume measurements total estimates obtained with CM & generalize or 
    2.70(0.09), tape measure (142 legs & 42 arms) OP reproduce. 
    volume 2.53(0.09), %   OP device initial cost 
    difference 6.97(1.18),  Overall, differed by < 5% for investment is 
    correlation coefficient 0.961  legs & < 7% for arms $19,500.00 
    Legs: automated edema % =   Demographic 
    14.2 (3.5), tape measure edema   information of 
    % = 15.4(4.4)   participants is 
    Arms: automated edema % =   missing 
    19.5(4.7), tape measure edema    
    % = 19.8(4.6)    
 
Bioimpedance and Optoelectronic Perometry and Dielectric X-Ray Absorptiometry 
 
Author, Year 
 
Study Objectives 
Study Design, 
Level of 
Evidence 
 
Assessments 
 
Psychometrics 
 
Population, Setting 
 
Summary of Results 
 
Limitations 
Ward, To demonstrate BIS Correlational BIS: SFB7 BIS predicted M increase in CG =13: women no BIS can quantify arm volume & Lacks accuracy of 
Czerniec, as a quantitative D2 Impedimed 3-1,000 tissue fluid of 421+/-384ml in history of lymphedema monitor increases in ECF; BIS-derived 
Kilbreath, assessment by Level IV kHz to predict affected arm of LG or BC. Strong correlations b/w volume predictions of fluid 
(2009) BCRT converting it to  volume. Proportional increase in TF of LG =23: women measurements of BIS & OP; volumes; currently no 
 direct units of  DXA: X-ray BIS 26.8+/-23.7% not sig clinically diagnosed Predicted V increased with true accurate 
 volume &  absorptiometry; different via paired t-test from with unilateral arm magnitude of difference (no quantification of ECF 
 comparing it to  total limb water OP proportional increase BCRL. constant bias) due to positive Error using arm 
 DXA & OP  used to determine 28.2+/-23.8% Resistivity slopes of correlations; length calculated as a 
   resistivity V difference in TF b/w arms by determination cohort Good agreement between proportion of stature 
   coefficients. BIS (mL) & OP:  r = 0.88 =66: data of women classification of lymphedema rather than exact arm 
   OP: 350S; volume V difference in ECF b/w arms drawn from a body BIS may be more appropriate in length; DXA 
   estimation by BIS (mL) & OP: composition database measuring early stage measured whole arm 
    r = 0.90 at the University of lymphedema b/c changes are vs. OP measured 
    V difference in ICF b/w arms Queensland mostly in fluid V vs. OP which 40cm from wrist 
    by BIS (mL) & OP: r = 0.80 Exclusion: considers overall volume  
     Pacemaker, pregnant (including fat content)  
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Water Displacement compared to Circumferential Measurement 
 
Author, Year 
 
Study Objectives 
Study Design, 
Level of 
Evidence 
 
Assessments 
 
Psychometrics 
 
Population, Setting 
 
Summary of Results 
 
Limitations 
Karges et al., To establish a Correlational WD volume Reliability when assessments of 14 F w/ a diagnosis of There was a high association Small study from one 
(2003) PT concurrent validity D2 Minus fingers (UE- UE volume compared: UE LE & receiving tx b/w CM & WD values. Though clinic, so 
 for WD volume & Level IV F) WD volume CM to WD volume from a specific both valid assessments of LE, generalizability is 
 girth measurements  CM (girth ICC: 0.99 women’s health clinic: one measurement cannot be limited. LE resulting 
 (CMs)  measurements) Coefficient of determination: convenience sample. replaced w/ the other during from different 
    0.98 Range: 44-71 y.o treatment because the resulting sources (traumatic 
    t = -7.58 BC related LE: 13 values varied b/w WD & CM. accident rather than 
    CM to UE-F Traumatic Accident: 1  side effect of BC tx) 
    ICC: 0.99    
    Coefficient of determination:    
    0.98    
    t =-3.88    
Megens et al., To compare IER & Correlational WD volumetry WD Volumetry: 25 F who had lymph Pearson’s R indicates good This was a small 
(2001) APMR test-retest reliability D2 CMs to calculate ICC: 0.99 node removal as part correlation b/w WD volumetry study w/ patients 
 of WD volumetry Level IV volume: CMs: of tx for unilateral BC & both types of CMs. Limits of receiving different tx. 
 & CIs (single  FSM & summed ICC: 0.99 Age range:35-67 y.o agreement value, suggests that Only one of the PTs 
 TCCV a.k.a. FSM  truncated cone Concurrent validity for WD subjects recruited from CMs provide high values for took measurements 
 & summed  calculation volumetry & FSM two sources, but 3 arm volume. the 2
nd 
visit, which 
 truncated cone   m difference is -47ml subjects’ data were  could impact 
 calculation).   SD: 164 ml excluded because they  reliability of reported 
    r = 0.94 had bilateral LE.  measures. 
    Concurrent validity b/w    
    volumetry & truncated cone    
    calculation    
    m: -137ml    
    SD: 118 ml; r = 0.97    
Meijer et al., Compare 4 cm Association 4 cm interval CM 1st Measurer: WD 30 F volunteers w/ LE No sig. difference between Not specified how 
(2010) (L) interval CM & 8 cm D2 8 cm interval CM measurement: as a complication of measurements of WD & 4 cm volunteers were 
 interval CM to WD Level IV WD Compared to 4 cm CM: p = BCT CM recruited. The results 
 Compare the   0.54, ICC: 0.87 R arm affected: 18 Sig. difference between from only two people 
 intrarater &   Compared to 8 cm CM: p = L arm affected: 12 measurements of: measuring were 
 interrater reliability   0.01, ICC: 0.71 Age mean: 56.4 WD & 8 cm CM compared. Not 
 of the above   4 cm CM compared to 8 CM: p Age range: Not 4 cm CM & 8cm CM specified if people 
 physical   = 0.00 cm, ICC: 0.8 provided IAR of WD, 4 cm CM, 8 cm measuring knew if 
 measurements   IAR:  CM: no sig. difference participants had LE 
    WD-Affected arm: p = 0.07,  IER of WD, 4 cm CM, 8 cm or not. The 2
nd
 
    ICC: 0.98 Unaffected arm: p =  CM: no sig. difference measurer’s ICC for 8 
    0.16, ICC: 0.95  The above indicates that results cm CM was very 
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    4 cm CM-Affected arm: p = 
0.35, ICC: 0.99 Unaffected arm: 
p = 0.47, ICC: 0.96 
8 cm CM-Affected arm: p = 
0.53, ICC: 0.99 Unaffected arm: 
p = 0.62. ICC: 0.91 
2nd Measurer: WD 
measurement: 
Compared to 4 cm CM: p = 
0.68, ICC: 0.86 
Compared to 8 cm CM: p = 
0.00, ICC: 0.8 
4 cm CM compared to 8 CM: p 
= 0.00, ICC: 0.92 
IAR: 
WD-Affected arm: p = 0.77, 
ICC: 0.97 Unaffected arm: p = 
0.36. ICC: 0.96 
4 cm CM-Affected arm: p = 
0.77, ICC: 0.96 Unaffected arm: 
p = 0.38, ICC: 0.9 
8 cm CM-Affected arm: p = 0.4, 
ICC: 0.92 Unaffected arm: p = 
0.2, ICC: 0.62 
IER between measurers: 
WD-Affected arm: p = 0.30, 
ICC: 0.91 Unaffected arm: p = 
0.17, ICC: 0.92 
4 cm CM-Affected arm: p = 
0.37, ICC: 0.88 Unaffected arm: 
p = 0.71, ICC: 0.85 
8 cm CM-Affected arm: p = 
0.54, ICC: 0.73 Unaffected arm: 
p = 0.67, ICC: 0.72 
 of WD & 4 cm CM are more 
similar to each other than results 
of 8 cm CM is to either of the 
other two measurements. 8 cm 
CM has acceptable IAR & IER 
as do WD & 4 cm CM. 
Measures should not be 
switched w/ each other for an 
individual patient because of the 
SD size of all measures. 
low. 
Sander et al., 
(2002) PT 
1.Determine the 
IER & IAR of 
upper extremity 
(UE) volume 
measurements from 
WD & CM 
methods 
2.Determine the 
relationship b/w 
Correlational 
D2 
Level IV 
WD & CM Preliminary power analysis 
(power = 0.80, effect size = 
0.35) determined sample size 
ANOVA & ICC used to 
determine IER & IAR 
reliability, Linear correlations 
used to establish relationship 
b/w WD & CM. LAA was used 
to determine if WD & CM are 
50 Fs, 25-85 y.o 
recruited from Y-Me 
Support groups & 
from PT clinics in 
Chicago area. 
All participants had 
primary or secondary 
LE 
Found high IER & IAR for both 
WD & CM. 
Correlation b/w WD & CM was 
strong, indicating a strong 
relationship b/w the two. 
Too much variability for the 
methods to be interchangeable 
Lack of blinding 
second examiner 
which could have 
contributed to the 
high reliability 
ratings 
Lack of diagnosis 
information on 
patients which may 
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 WD & CM   interchangeable. SEM   make more difficult 
methods calculated for all measurements. to generalize data 
3.Determine   
whether WD or CM Arm Data: IER for WD &  
measurements are CM.99, IAR for WD & CM .99  
interchangeable. Range of LAA from 479 to 655  
 mL, range from this % was 15-  
 19%.  
 Hand Data: Range of ICCs for  
 IER from .91 to .98. IAR ICCs  
 ranged from .92 to .99. LAA  
 ranged from 108 – 152. , range  
 from this % was 18 – 24%.  
Taylor et al., To determine Cross-sectional CM: distance from Both arms measured 2x by 2 N=66 women recruited High IER of CM methods & Upper boundary of 
(2006) PT reliability & comparison fingertips to upper raters & calculated ICC via from Breast Centre WD WD 65% of distance 
 validity of how two D2 boundary (30 to ANOVA and the Lymphedema CMAL higher validity than CM from elbow 
 different methods Level IV 60cm in 10 cm CM IER all groups L & R arm: Clinic at Westmead due to smaller SEM relative to olecranon to 
 of CM compare to  increments) 0.98 to 0.99 Hospital in Sydney, WD acromion 
 WD  CMAL: calculated CMAL IER all groups L & R Australia CMAL more accurate b/c lower Inclusion/ exclusion 
   from 4 anatomical arm: 0.97 to 0.99 CG: 25 LAA w/ WD criteria not detail 
   landmarks BC LG BCG w/out arm LAA: CM & WD should not be specified 
   WD ICC: IER lymphedema: 22 used interchangeably but can be Bias: Assumes WD 
    CM: 0.99 BCG w/arm used individually has higher validity 
    CMAL: 0.99 lymphedema: 19 CM methods more efficient than due to belief that arm 
    WD: 0.97  WD segments are ellipses 
    CG non-dominant arm: ICC   not truncated cones, 
    IER   hence surface 
    CM: 0.98   irregularities not 
    WD: 0.94   captured; thickness of 
    Pearson coefficient r=0.98 b/w   measure in tape 
    CM & WD   interferes with 
    LAA R arm:   measurement 
    CM (overestimated WD by 5%)    
    CMAL (overestimated WD by    
    5%)    
    R&L SEM CMAL: 64.5-    
    65.4mL vs. SEM CM: 66.6-    
    71.0mL    
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Tewari et al. To establish Correlational WD & CM CM UE Volume Estimation 98 F volunteered The results of the CM Participants were 
(2008) AJS accuracy & D2 (truncated cone) Range narrow measuring tape: 11 were excluded measurements are almost excluded because 
 compare WD Level IV  1021.33-3775.05 ml 87 F participated equivalent to the measures they could not use the 
 measurements w/   Range wide measuring tape: M: 58.6 y.o obtained w/ WD. Narrow tape water tank. A larger 
 truncated cone CM   1015.28-4125.56 ml Range: 17-81 y.o measurement correlates slightly tank was not 
 using wide &   r = 0.95  better w/ WD than wide tape. provided to 
 narrow tape   WD UE Measurement  Measuring tape has the accommodate these 
    Range: 1075-3790 ml  advantages of no size/length individuals, thus the 
    Comparisons:  limit for use, is more portable, & study had a limited 
    CM (narrow tape) to WD  can be used on patients w/ size for the limb &/or 
    r = 0.92 (CI: 0.89-0.94)  wounds. CMs did result in LE. Study was a 
    CM (wide tape) to WD  higher measurements than WD. convenience sample, 
    r = 0.88 (CI: 0.84-0.91)   so it will have low 
    Using BMI: CM to WD   generalizability. 
    Narrow measuring tape:    
    BMI: r = 0.792-r = 0.94    
    Wide measuring tape:    
    BMI: r = 0.70- r = 0.93    
 
Cost-Related Study: Bilir et al, 2012 
 
Author, Year 
 
Study Objectives 
Study Design, 
Level of 
Evidence 
 
Assessments 
 
Psychometrics 
 
Population, Setting 
 
Summary of Results 
 
Limitations 
Bilir et al., To compare Historical BIS: Pt is assessed Base-Case Analysis: A hypothetical at-risk The base-case analysis indicated There is little 
(2012) AJMC combined D3 at every follow-up Savings of $315,711.00 when population was that when BIS assessment is longitudinal data on 
 tx/assessment cost Level V visit w/ BIS BIS assessment is used instead determined from a used $315,711.00 per year is LE. 
 over 1 year as  CS: Pt must self- of CS hypothetical saved when compared to CS. Variability of 
 determined by  report symptoms to Univariate sensitivity population of 1 million Only in the most positive characteristics is 
 either BIS or CS  then be assessed. analyses: w/ insurance coverage. scenario of the extreme value limited by a 
 assessments  The two prevalent Single parameters changed to The result was 627 multivariate analyses (the population model 
   methods in use are investigate savings when BIS is patients. scenario in which every outcome created w/ averages. 
   circumferential UE used instead of CS. Parameters used in for the patients is the minimal No non-cost benefits 
   & WD Scenario Analyses: determining at-risk cost) is BIS less cost effective or challenges were 
    Compression sleeve: population were as than CS. In the most negative explored w/ BIS or 
    Removing sleeve from CS follows: F, age>18, scenario annual cost of patients CS. 
    scenarios & adding custom patients diagnosed w/ receiving CS is $3,049,779.00 &  
    sleeves to BIS yielded savings BC/year BIS is $1,422,250.00. In the  
    of approximately $5,000.00  most positive it is $1,300,702.00  
    Pneumatic Pump Use:  & 1,627,528.00 for CS & BIS  
    If pumps are removed from  respectively. Early detection  
    model BIS savings are  cited as a reason for the  
    approximately: $136,000.00  healthcare savings incurred by  
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    Higher Tx Costs for BIS- 
Detected Cases: 
When 25% of cases require 
CDT, BIS still yields a savings 
of approximately $126,000.00 
Low-/High-risk Populations 
Only: 
BIS yields savings of 
approximately, $150,000.00 
Infections: 
Low infection projection yields 
approximately $400,000.00 in 
savings 
 BIS. This supports the use of 
BIS assessments as a cost saving 
component of identification & tx 
of LE. 
 
 
Recommended articles from Impedimed (Added on April 18, 2017) 
 
Author, 
Year 
 
Study Objectives 
Study Design, 
Level of 
Evidence 
 
Methods & 
Outcome Measures 
 
Population/Setting 
 
Summary of Results 
 
Limitations 
Laidley & To assess role of Case-Controlled Patient Charts 326 women: breast cancer patients 286 women: normal L-Dex score Retrospective review 
Anglin BIS in clinical Retrospective reviewed from from two surgical practices Subclinical BCRL incidence: 12.3% (40 women) limits validation of 
(2016) practice to detect Study Nov.2008-July2013; M: 56.2 y.o w/rate of 4.3% for SLNB & 26.7% for ANLD these findings; 
 & monitor O3 Pts. Monitored 210 women: SLNB SLNB: mean time to positive LE assessmen via L- limited information 
 subclinical LE Level II preoperatively; 116 women: ALND Dext: 5.6 months from preoperative assessment & available in charts 
   assessed every  mean follow-up from subclinical BCRL diagnosis Unable to evaluate 
   3months within 2 y.  15.7 months. other factors (BMI & 
   post-surgery; L-dex  ALND: mean time to positive LE assessment: 7.5 radiation) that 
   U400 used for  months from preoperative assessment & mean contributed to 
   measurement  follow-up from subclinical BCRL diagnosis 13.4 increase risk in LE 
     months. Reasons why LE tx 
      began could not be 
      determined due to 
      clinician discretion 
Soran et al. To detect and Controlled BIS via L-Dex U400 180 participants w/breast cancer Incidence of clinical LE in CG: 36.4% at 12 month Small sample size; 
(2014) compare incidence Clinical Trials CM via tape enrolled in the Maggee-Women’s follow up; sig. higher than pre-op group: 2.8% not generalizable; 
 of subclinical LE (prospective measurements Hospital Breast Cancer Center LE incidence of clinical LE in 19 month follow-up considers only 
 between patients cohort study) E3 Divided into 3 Education, Monitoring, Early No pre-op & pre-op group incidence of clinical LE: ALND 
 prospectively Level II groups: Detection, and Prevention Program 4.4% (20 month follow-up)  
 monitored by BIS  Pre-op group: newly prospective database. Subclinical LE diagnosed in 28 patients in the pre-op  
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 & patients  diagnosed patients  group and 17 patients in the no pre-op group  
assessed via CM. w/baseline L-Dex Reduction rate of clinical LE 32%95.6% of patients 
 measurements prior diagnosed with sublinical LE via BIS did not 
 to surgery and progress to clinical LE 
 monitored via L-Dex 33% of women monitored via L-Dex measurements 
 No Pre-op group: were diagnosed with subclinical LE and given early 
 Patients showed no intervention. 
 signs of clinical LE  
 via CM and initial  
 BIS reading was 6  
 months post surgery.  
 CG: patients who had  
 preoperative Baseline  
 L-Dex measurements  
 but monitored w/ CM  
 due to lack of  
 insurance coverage.  
 Average follow-up  
 was 19 (pre-  
 op),19(CG) , and 25  
 (post-op) months  
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GENERAL ABBREVIATIONS KEY: 
A: Affected 
ALND: Axillary Lymph Node Dissection 
ANOVA: Analysis of Variance 
AUC: Area under the curve 
BC: Breast Cancer 
BCG: Breast Cancer Group 
BCRL: Breast cancer-related lymphedema 
BCS: Breast cancer survivors 
BCT: Breast Cancer Treatment 
BIA: Bioimpedance Analysis 
BIS: Bioimpedance Spectroscopy 
B/w: Between 
CAML: Circumferential Anatomical Landmarks 
CC: Concordance Correlation 
CG: Control Group 
CI: Confidence Interval 
CM: Circumferential Measurement 
CS: Current Standard 
DMM: Disk model method 
DXA: Dual x-ray absorptiometry 
ECW/ECF: Extracellular Water/Fluid 
EDGE Task Force: Evaluation Database to Guide 
Effectiveness 
EIS: Electrical Impedance Spectrograph 
F: Female 
FSM: Frustum sign method 
hx: history 
I: Intervention 
IAR: Intra-rater reliability 
IER: Inter-rater reliability 
ICC: Intraclass correlation coefficients 
ICF/W: Intracellular Fluid/Water 
IOV: Infrared optoelectronic volumetry 
LAA: Limits of Agreement Analysis 
LCC: Lin’s Concordance Correlation 
LE: Lymphedema 
LG: Lymphedema group 
LOA: Limits of agreement 
LV: Limb Volume 
LYM: Lymphometer 
M: Mean 
MDC: Minimal Detectable Change 
MCID: Minimal Clinically Important Difference 
MFBIA: Multiple Frequency Bioimpedance Analysis 
OM: Outcome Measure 
OP: Optoelectronic perometry 
OT: Occupational Therapist 
PT: Physical Therapist 
RD: Relative Differences 
R&L: Right and Left SD: 
Standard deviation 
SEM: Standard Error of Measurement 
SFBIA: Single Frequency Bioimpedance Analysis 
 
Sig: Significance 
SLNB: Sentinel Lymph Node Biopsy 
SLN: Sentinel Lymph Node Dissection 
TF: Total fluid 
TDC: Tissue Dielectric Constant 
w/: with 
Tx: Treatment 
U: unaffected 
WD: Water Displacement 
WV: Water Volumetry 
y.o: Years old 
 
JOURNAL ABBREVIATIONS KEY: 
AJMC: American Journal of Managed Care 
AJS: ANZ Journal of Surgery 
AO: Acta Oncologica 
APMR: Archives of Physical Medicine & 
Rehabilitation 
APS: Annals of Plastic Surgery 
ASWC: Advances in Skin and Wound Care 
BCRT: Breast Cancer Research & Treatment 
CI: Cancer Investigation 
JSO: Journal of Surgical Oncology 
(L): Lymphology 
LRB: Lymphatic Research & Biology 
PT: Physical Therapy 
RO: Rehabilitation Oncology 
SCC: Support Care Cancer 
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Summary of Key Findings: 
Summary of Outcome Studies 
Circumferential measurements (CM), water displacement (WD), and bioimpedance (BIS) are highly recommended due to  
their reliable and valid psychometric properties and clinical utility (Perdomo et al., 2014). BIS is an effective tool for di agnosis 
of well-established BCRL (Seward et al., 2016). Shah et al. (2013) and Bundred et al. (2015), a descriptive study, found BIS to 
be valid in detecting early onset lymphedema post-surgery, however, Seward et al. (2016), found that there is not enough 
evidence to conclude that BIS detects breast cancer related lymphedema earlier than other measurement techniques. 
Additionally, BIS was found to effectively monitor lymphedema from baseline to post-surgery via tracking reductions in L- 
Dex scores (Shah et al., 2013). Presumably CM cannot differentiate between intracellular fluid and extracellular fluid because 
measurements are taken externally. Evidence suggests that BIS can make a distinction intra- and extracellular fluid 
accumulation (Shah, 2013). When compared to other measurement methods, BIS is more reproducible (Adriasenssens et al., 
2013; Cornish et al., 1996), time efficient, sensitive, quantifiable, portable and easier to operate (Ward et al., 2006).  
Additionally, BIS was found to be better accepted by clinicians, therapists, and patients (Ward et al., 2006). BIS quantified 
significant differences between dominant and non-dominant limbs (Fu et al., 2012; Ward, 2006). Soran et al. (2014) found that 
participants assessed via BIS to monitor lymphedema had significant lower incidence rates of clinical lymphedema compared 
to participants assessed via CM. Similarly, Laidley and Anglin (2016), demonstrated that BIS identified patients in need of 
BCRL treatment when incorporated early into routine clinical practice and used as part of routine follow-up, resulting in 
reduced chronic clinical BCRL. The consistency of these outcome findings suggest that BIS may be the most suitable 
assessment to use when evaluating lymphedema. 
 
Summary of Descriptive Studies 
The literature described a variety of methods and comparisons among lymphedema assessments. WD and CM, regarded as 
the former gold standards to measure lymphedema, were commonly compared in the research. Deltombe et al. (2007) found 
that frustum sign method calculations had higher reliability compared to disk model method calculations of CM. 
Additionally, Taylor et al. (2006) found that CM of anatomical landmarks was more reliable and valid than CM (wrist to 
axilla) due to its smaller SEM when compared to WD. CM and perometry (OP) demonstrated high inter-rater reliability and 
intra-rater reliability when compared to WD (Deltombe et al., 2007). Results from Karges et al. (2003) also support  
physical measurements having a high correlation with each other using WD and two types of CM. Truncated cone 
measurements were shown to underestimate volume compared to OP (Czerniec et al., 2010). Meijer et al. (2004) found high 
correlation between 4 cm interval CM and WD, but not 8 cm interval CM and WD. Megens et al. (2001) found similar 
correlation results with the same physical measurements as Karges et al. (2003). The strong relationships found between 
WD and CM provided a comparison in the literature to assist in determining the psychometric properties  of 
OP and BIS. According to Czerniec et al. (2010) BIS showed slightly higher interrater reliability when compared to 
truncated cone measurements. While BIS was shown to be the more favorable option in most studies, it may not be as 
accurate in other populations, particularly in individuals with bilateral lymphedema (Warren et al., 2007).  
 
The research showed BIS and OP to be valid measurements of lymphedema. According to Moseley, Piller and Carati  
(2002), BIS was a more accurate assessment of limb fluid change while OP provided an accurate determination of total 
limb volume change. Both were equally valid in measuring leg volume changes and were non-invasive and quick methods 
to assess secondary lymphedema. OP, water volumetric, and CM also have high intra-rater reliability (Hidding et al., 2016; 
Jain et al., 2010). Both Ward et al. (2009a,b) studies demonstrated that BIS and OP were strongly correlated. In contrast, 
Bundred et al. (2015) found moderate correlations between BIS and OP, concluding that BIS may be a suitable alternative 
to OP in detecting lymphedema. 
 
Ward et al. (2009a) found good limits of agreement when classifying lymphedema, however BIS and OP demonstrated 
relatively poor limits of agreement due to having different units of measurement; hence these methods cannot be used 
interchangeably but can be used independently. The inability to interchange methods of measurement was supported by 
Bilir et al. (2012), Czerniec et al. (2010), Czerniec et al. (2009), Karges et al. (2003), Megens et al. (2001), Meijer et al. 
(2004), Moseley et al. (2002), Perdomo et al. (2014), Sander et al. (2002), Ward et al. (2009a, b) and Warren et al. (2007). 
Similarly, Ridner et al. (2007) and Mayrovitz et al. (2000) both found strong correlations between CM and OP and 
moderate correlations between CM and BIS methods. From the correlations found in this study, they concluded that each 
assessment was valid in measuring upper limb lymphedema. Adriasenssens et al. (2013) found OP to be beneficial because 
it has reproducibility, ease of use, and the results of its volume estimates were between WD and CM. Ward et al. (2009a) 
noted that a limitation of OP in their study was its inability to detect lymphedema close to  axilla, indicating lower validity 
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Implications for Hospital/Clinic Purchaser of assessment products: 
This critical appraisal will provide hospital and clinic purchasers with informative research regarding the comparisons of BIS, 
OP, and CM. Our analysis of the literature will potentially impact the decision-making of purchasers who may need to 
consider assessments most suitable for their setting, population, and budget. The evidence demonstrated that BIS was 
preferred under many conditions (Perdomo et al., 2014; Seward et al., 2016; Warren et al., 2007). Bilir et al. (2012) proposed 
that using BIS was the most cost effective method due to its high sensitivity in detecting and monitoring lymphedema. A 
barrier to using BIS in clinical practice may be cost and lack of insurance coverage, resulting in using CM which is not as 
effective as detecting subclinical lymphedema (Soran et al., 2014). Additionally, BIS was found to have strong correlations 
with previous gold standards such as CM and WD (Czerniec, 2010; Fu et al., 2012; Ridner et al., 2007). was found to be more 
time-efficient (Ridner et al., 2007; Ward, 2006), valid (Ward et al., 2009a) and reliable (Hidding et al., 2016; Jain et al., 2010 ) 
when compared to CM and OP. Fu et al. (2012) found that BIS was time-efficient when compared to CM. Although OP and 
BIS were strongly correlated in the literature, OP demonstrated less sensitivity and accuracy in measuring change in ECF 
(Czerniec et al., 2010; Moseley et al., 2002). Overall these findings will allow purchasers to present this information to 
insurance companies and other sources of reimbursement, in order to facilitate coverage for the costs of BIS.  
 
Implications for Consumers (Patient): 
  
 
Implications for Practitioners: 
This information will allow lymphedema specialists (OTs & PTs) to be more certain that they are using valid and reliable 
assessments in order to provide optimal care for their clients with lymphedema of the limbs. They should use this critical 
appraisal as a supplement to their clinical reasoning to select an assessment that is in the best interests of their clientele. If 
clinicians make use of this critical appraisal, their sessions will focus more on treating lymphedema and meeting client 
needs rather than spending a majority of the time assessing lymphedema. Clients rely on clinicians for the best care 
possible and many times, rehabilitation directors are unaware of what is best for clients because they do not work directly 
with them. Clinicians have the duty to aid in the development of programs that adopt instruments such as BIS in their 
clinics and they also play a primary role in providing this information to supervisors and directors who can then work 
toward insurance coverage and reimbursement. The literature supports that clinicians could be confident in implement ing 
BIS into practice due to its concurrent validity with other lymphedema assessments available on the market (Jain et al.,  
Based on the literature examined, BIS appears to be a more sensitive (Bilir et al., 2012; Bundred et al., 2015; Sha h et al., 2013) 
and time-efficient (Fu et al., 2012; Ridner et al., 2007; Ward, 2006) assessment of lymphedema in comparison to CM and OP . 
As a patient it is imperative to self-advocate for baseline lymphedema measurements prior to undergoing surgery. Evidence 
shows that this will aid in earlier detection of lymphedema. When considering assessment options, BIS would be the preferred 
assessment to measure preoperative baselines because its high sensitivity allows for earlier detection of lymphedema (Bundred  
et al., 2015; Shah et al., 2013). BIS has the ability to carefully monitor LE, diagnose subclinical LE, and initiate early 
intervention, thus reducing the incidence rates of clinical lymphedema (Soran et al., 2014). Early diagnosis of lymphedema vi a 
BIS has shown potential to lead to a better prognosis because treatment can be started sooner rather than later, resulting in 
overall lower total treatment costs (Bilir et al., 2012). Additionally, evidence shows that treatment of lymphedema implement ed 
earlier may prevent chronic lymphedema (Bundred et al., 2015; Laidley and Anglin, 2016).  
BIS also takes less time (5-6min) to administer which provides ease of scheduling for consumers (Ridner et al., 2007). Overall, 
this critical appraisal gives an extensive synthesis for any consumer who desires to be well-informed about his/her treatment 
options. 
in these results. According to Ward et al. (2009b) BIS quantifies upper limb volume and detects changes in limb volume. 
Similarly, Czerniec et al. (2009) found that BIS detected localized changes with a higher degree of sensitivity than total 
limb volume measures because BIS has the ability to differentiate between ECF and other fluids. Therefore, they concluded 
that BIS could detect localized lymphedema more readily than OP (Czerniec, et al.,  2009). 
 
An overall finding in Czerniec et al. (2010) was that physical measurements (truncated cones, perometer, BIS) are 
correlated with each other. Bilir et al. (2012) concluded that in all but the most ideal situation, BIS is a more cost -effective 
method of measurement for lymphedema when compared to standard methods. BIS is also the ideal measurement for early 
stages of lymphedema and is also effective for later stages (Bundred et al., 2015). Although we found a variety of studies on  
lymphedema assessments, their results and conclusions were similar in suggesting that BIS may be the most suitable 
assessment in comparison to CM, WD and OP to use for the evaluation of lymphedema. 
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Implications for Researchers: 
A majority of our studies noted that lymphedema is not well defined, which makes it difficult to compare among studies. Also,  
in most cases, the research that utilized control groups was not blinded (Hidding et al, 2012), however, in an example when 
blinding was partially utilized, there was potential for inaccurate reliability results (Sander et al., 2002). It might be imp ortant 
for researchers to establish normative ranges for individuals based on height, weight, and other integral characteristics. B IS 
currently measures unilateral lymphedema and is not as accurate for bilateral lymphedema (Warren et al., 2007). Normative 
values may also provide a comparison that would allow BIS to measure bilateral lymphedema (Dylke et al., 2016; Ward 2006). 
BIS measures cannot be compared to other measures without being converted; this implies a need for a standardized equation 
that can be used across all settings (Ward, 2006; Ward et al., 2009b). Researchers should be aware of these weaknesses that 
exist because of the nature of assessing lymphedema. 
 
Implications for Evidence Researchers: 
  
 
Bottom Line for Occupational Therapy Practice/ Recommendations for Better Practice: 
Occupational therapy practitioners who specialize in lymphedema need to understand that CM and WD used to be 
considered the ‘gold standard’ for measuring lymphedema. Unfortunately, these measures do not take into account other 
non-lymph types of edema. BIS has the capacity to discriminate between differing fluids within the limbs (Czerniec et al., 
2009). Other benefits to BIS include its portability, ease of use, time efficiency, reproducibility and quantifiability (Ward et 
al., 2006). In addition to discriminating between types of lymphedema, BIS also has the ability to detect lymphedema 
earlier than other assessment methods due to its level of sensitivity (Bilir et al., 2012; Czerniec et a l., 2010; Czerniec et al. 
2009; Hidding et al., 2016). Early detection generally leads to earlier treatment and ultimately lower long -term cost and 
better outcomes for patients (Bilir et al., 2012; Bundred et al., 2015). Early detection could be a key factor in determining 
between acute and chronic lymphedema, which is important for OTs to consider (Bundred et al., 2015). Occupational 
therapy practitioners must use discretion and decide if implementation of these measurement tools are integral to the ethics  
of their practice and the needs of their client population. 
Evidence regarding early detection and diagnosis was not searched for systematically, but was included in some research that 
addressed measurements. In the scope of evidence we examined, BIS was most effective at detecting lymphedema because it is 
a more sensitive measure than CM, WD, and OP (Bilir et al., 2012; Czerniec et al., 2010; Czerniec et al., 2009; Hidding et al ., 
2016). Self-report was also not a focus of our research, but was used in five articles we found (Bilir et al., 2012; Czerniec et al., 
2010; Hidding et al., 2016; Perdomo et al., 2014; Ridner et al., 2007). Czerniec et al. (2010) suggests that BIS and self -report  
are both sensitive to small changes. Robotic 3D scanning is another form of lymphedema measurement that was seen during our 
searches. It is a new technology that may be effective in lymphedema measurement. Future research should be conducted on 
early detection and diagnosis of lymphedema as well as self-report and robotic measurements. For further information 
pertaining to early diagnosis or robotic 3D scanning, please refer to the bottom of the reference list. 
2010). Additionally the research found that BIS was reliable (Jain et al., 2010), valid for early detection (Shah et al., 201 3), 
valid in measuring leg volume changes (Moseley et al., 2002), time-efficient (Fu et al., 2012; Ridner et al., 2007; Ward, 
2006), economically beneficial (Bilir et al., 2012), client-preferred (Ward, 2006), and user-friendly (Fu et al., 2012) when 
compared to other lymphedema assessments. 
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Involvement Plan 
 
After meeting with Shaffer and discussing our comparisons of CM, BIS, and perometry we decided to 
translate our findings by providing an in-service presentation to her lymphedema team and other MultiCare 
employees. Shaffer would like us to focus primarily on the two assessments she uses in practice: CM and BIS, and 
give a brief overview of perometry. The purpose of our presentation is to inform her colleagues about the benefits of 
using BIS to assess unilateral lymphedema from both a patient and practitioner perspective.  
Shaffer is a pragmatic user of the L-Dex (a BIS device) because of its easy administration, reliability, time 
efficiency, and cost effectiveness. However, due to Medicare and other federally funded insurance companies 
providing limited to no coverage, she is unable to utilize the L-Dex for many of her patients. We have been 
corresponding with Impedimed, the creators of the L-Dex, and according to their insurance representative, 
Washington is located in the Noridian Medicare region, which does not provide consistent coverage of the L-Dex or 
any BIS measure. Therefore, Shaffer would like us to include this piece of information in our presentation and offer 
potential solutions to encourage our regional Medicare administrative contractor (MAC) to initiate coverage.  
We plan to gather in-service outcome data by distributing a survey to our audience to measure what 
information they gained from our presented research and ideas they have to advocate for insurance coverage of the 
L-Dex. Additionally, Shaffer requested we develop a brochure she can provide to inform her patients about t he 
benefits of using CM and BIS how these assessments may impact lymphedema treatment. Shaffer requested that 
brochure be simple, easy to read, but informative in order to avoid confusing any of her clients.  
ARC: Availability, Responsiveness, Continuity 
 
The knowledge translation of the research found and characteristics of Shaffer and MultiCare apply best to 
the ARC model: Availability, Responsiveness and Continuity. Although MultiCare currently uses the L -Dex, the 
issue with federal insurance not providing coverage for BIS is a complex social context that may impact the 
effectiveness of our research. 
Availability 
 
The ability to diffuse the information we have compiled to the largest group of people possible in order to 
see long term effect may be seen as a barrier. The audience receiving the data limits how far it may be able to be 
spread. At this time, the information we are trying to convey is limited to the therapists and staff of MultiCare.  
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Another factor that presents a possible barrier is that BIS is not currently covered by Medicare, which is the insurer 
of a majority of MultiCare patients. On the other hand, it could be considered a facilitator that several of the private 
insurance companies are currently reimbursing for BIS measurements now and Medicare may follow the trend at 
some point in time. Shaffer mentioned that MultiCare as an entity may be willing to complete a research study in 
order to collect the data needed to persuade the Medicare representative for our region into accepting BIS 
measurements as valid and reimbursable by Medicare. Unfortunately, research calls for more random control trials 
that are longitudinal and follow patients throughout the entire process of detection and treatment in order to provide 
proof of an overall cost reduction. This process would take several years which could be considered a barrier as 
well. 
Responsiveness 
 
One factor that may be a barrier or a facilitator is how the information that we present to MultiCare is 
received. People may choose to accept or reject the data presented on an individual basis. Additionally, anyone who 
receives the information, including individual therapists, managers, department heads, etc., also has a choice as to 
what they will do with the information once it is received. If those who receive the information feel that action needs 
to be taken, so that they can continue to use BIS without taking a financial loss, how they implement that change 
may be limited to the power structure and decision making process that MultiCare has in place. Great intentions are 
not generally enough to make long term change. Hard work and perseverance are usually required and those who try 
to implement change may either be met with support or be presented with barriers to their attempts. 
Continuity 
 
This knowledge has the potential to make a long-term change if it plays a part in Medicare accepting BIS as 
a reimbursable measurement tool for lymphedema. This would be a huge facilitator to long term continuity, 
however, the time it would take to achieve this goal is unknown. Currently, a large number of the lymphedema 
therapists at MultiCare are already using BIS to measure lymphedema in their patients, therefore, accepting and 
implementing this into practice over a long period of time consistently should not be difficult to do. It may be 
considered a barrier for MultiCare to have to train anyone who is not already using BIS due to the financial cost and 
time that it may take. On a broader scale, it may be a long-term barrier for patients to utilize BIS due to insurance 
companies not providing coverage. 
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An outline of the scheduled dates for the completion of these tasks/products 
 
Task/Product 
(1a-f above) 
Deadline 
Date 
Steps w/ Dates to achieve the final outcome Completion 
Date 
Presentation 
and Outcome 
Survey 
04/14/2017 Shaffer is working towards setting up a quarterly meeting prior to 
the deadline for our final paper (sometime in April). There is no set 
date for this meeting yet, but we plan to complete our presentation 
by or before March 30, 2017 in order to be fully prepared for 
whenever this meeting might occur. Cullyn will be in charge of 
developing questions for the outcome survey and will assign tasks 
to the group as needed. Divina will be in charge our PowerPoint 
presentation and will also assign tasks to the group as needed. 
3/26/17 
Brochure for 
Patients 
04/14/2017 This brochure will be completed prior to our presentation (April 
2017) with Shaffer and colleagues. This will be helpful to be able 
to distribute to multiple therapists at once. We will begin working 
on this brochure immediately (February 22, 2017). Connie will be 
in charge of completing the brochure and will assign tasks to the 
group as needed. 
3/20/17 
Poster 
Presentation 
05/03/2017 The printing of this poster will be completed on Monday, May 1, 
2017. We will begin work on this poster April 1, 2017, and will 
complete the poster 3 days following our presentation with Shaffer 
and her colleagues. Jessica will be in charge of completing the 
poster presentation and will assign tasks to the group as needed. 
 
Time lapse 
video demo 
04/2017 This time lapse will need to be conducted at Shaffer’s office with a 
client, so that we can demonstrate the difference in time efficiency 
between the L-Dex and CM to those at the poster presentation; 
sometime in March or April. 
4/30/17 
 
 
We will evaluate the outcome of all of these projects and the information shared from the research we have 
conducted through administration of the outcome survey to all lymphedema therapists present at the quarterly 
meeting in April, 2017. We also plan to meet with Shaffer following that presentation to debrief and reflect upon the  
effectiveness of the presentation and what steps need to be taken for following research groups (conference call). In  
  
LYMPHEDEMA ASSESSMENTS 35 
 
 
 
 
addition to these steps we would like to meet with our chair (George Tomlin) to ensure we have adequately 
distributed the information we gained from our research. 
Activities and Products Completed 
 
Brochure for MultiCare Clients (Appendix A) 
 
The intention of the brochure was to create a product for the consumer that would clearly 
 
inform them of the choices available to them for lymphedema assessment and the advantages and possible 
disadvantages of each. Providing consumers with opportunities to make informed decisions related to  their health 
care is empowering and increases health literacy. Through our research and conversations with Heidi Shaffer, it was 
determined that CM and BIS, via L-Dex, were the two assessments utilized by MultiCare lymphedema specialists. 
Within the brochure, we provide basic information about the two different assessments which include a definition of 
both assessments, their pros and cons, why it is important for them to have this information, and additional 
resources. 
Currently, the CM technique is bundled into the evaluation billing code for lymphedema assessment and is 
typically reimbursed by insurance. Unfortunately, BIS is a fairly new assessment technique, and as such, is only 
sporadically reimbursed by insurance. MultiCare physicians have stated that they prefer to use BIS the majority of 
the time. With reimbursement being at the discretion of insurance companies, there is a possibility that there will be 
a cost to the consumer for this assessment method if used. MultiCare has lowered this cost as much as possible and 
essentially only requires the consumer to cover the cost of supplies at $70. This is a large part of why MultiCare 
wanted a brochure created. The consumer has to agree to cover this cost (if not reimbursed by insurance) and they 
are more likely to do so if they clearly understand the advantages of BIS. 
Creating the brochure was fairly straightforward and simple. Determining what needed to be included 
required conversation between Shaffer and our group which was not difficult, but time consuming. Edits were 
decided upon as a group and the final product was completed using Microsoft Publisher software. In addition, we 
created an outcome measure for the therapists to track the brochure’s usefulness. Suggested outcomes questions 
were also provided with the brochure that Shaffer and her team could use to gather data on the knowledge 
translation to clients via the brochure. 
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In-service Presentation for MultiCare Staff (Appendix B) 
 
Upon meeting with Shaffer, after completing the research she had requested, we were able to confirm that 
BIS was the preferred assessment measurement. Due to the fact that the majority of therapists at her clinic, including 
herself, already utilize BIS and understand the benefits, our research provided empirical evidence to confirm what 
her and her colleagues already believed to be true. The insurance coverage issues identified throughout the research 
became an additional focus area of this knowledge translation project. Shaffer felt that it would be most appropriate 
for us to present information on what the staff can do with this new evidence and how they can be a part of the 
bigger picture. This bigger picture, long term effect is that of convincing insurance companies, mostly Medicare, 
that BIS is a reliable, valid, and safe assessment for diagnosing and measuring lymphedema. Along with measuring 
lymphedema, BIS has been shown to be capable of early detection of lymphedema if used in the early stages of 
treatment. Early detection has the potential to decrease incidence as well as total treatment time. There are several 
ways that MultiCare can help to advocate for BIS to become a covered lymphedema assessment, as well as a tool to 
be utilized for early detection, which were also discussed during the in-service. 
Originally, Shaffer intended for us to present this information to all of therapists on staff at her MultiCare 
location. Unfortunately, due to unavoidable scheduling conflicts, we were unable to attend and present at her 
facility’s quarterly meeting. Shaffer stated that she preferred for us to present the information to Olsen, who 
oversees all the MultiCare lymphedema specialists in this region. 
Google slides software was utilized to compile the data and information needed to present all of the 
findings and future implications of our research project. Acquiring the information needed in relation to insurance 
coverage of BIS and early detection was a difficult, but rewarding process. We reached out to Impedimed, the 
company that manufactures the L-Dex, to seek whatever knowledge they possessed on this topic. Many reciprocal 
emails and phone calls led us to Fustgaard, who agreed to meet with us in person to discuss our research findings 
and shared with us some of what their company is doing to advocate for insurance coverage of BIS. The meeting 
with Fustgaard was very informative and in that process, we received some new research articles as well. Permission 
to share what we had discussed with her in our presentation was given verbally and in written format . After meeting 
with Fustgaard, we felt that we had the necessary data to complete our PowerPoint and schedule a time to present it 
to Olsen of MultiCare. Olsen informed us of what collaborations MultiCare already have in the works to address  this 
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issue as well as what they do at the therapist level to contribute to the growing body of evidence related to this topic. 
The results of the collaborations between Olsen and Fustgaard were informative for all parties involved. We had 
Olsen and Fustgaard fill out a qualitative questionnaire in order to measure outcomes of the research findings.  
Outcomes and Effectiveness 
 
Statement of Outcomes (Appendix C) 
 
We presented our findings and conclusions to three individuals Shaffer, Fustgaard; and Olsen in separate 
meetings. We created a qualitative outcomes questionnaire for these three individuals to fill out after our individual 
presentations for Fustgaard and Olsen. Our collaborating clinician filled out the survey after working with us 
through the entire process. 
In her response to our questionnaire, Shaffer reported that our research seemed to comprehensively explore 
tools used to measure lymphedema. Before our presentation, she had not been aware that BIS measurements are 
covered in other regions of the United States. In her response, Fustgaard expressed that she would like to collaborate 
with “researchers…to approach regional clinics”. We received a separate email from Fustgaard on 04/25/2017 
stating that she spoke with the Impedimed “head of clinical...about your paper, and we feel it’s a fair, balanced 
review of the technology.” Olsen thanked us for providing “updated information and work [we] did to identify payer 
information” on her questionnaire. She did not report either learning anything new from our presentation or would it 
change how she advocates for coverage, but she felt we omitted no crucial information.  
One of the products we created for our collaborating clinician was an informational brochure comparing 
CM and BIS (the two assessments currently offered at Multicare). With the brochure, we included suggested 
outcomes questions for Shaffer to use to collect data on the interest in and response to the brochure. Tracking how 
many brochures are taken over the course of a three month, six month, and year period is a suggested outcome 
measure in that document. We suggested the clinician inform staff of this tracking because they may be able to help. 
Effectiveness of the client brochure 
A client brochure comparing the two measurements (L-Dex and circumferential measurement) provided at 
Shaffer’s lymphedema clinic was given to MultiCare for dissemination. The brochure provided pros and cons along 
with education on how each measured lymphedema differently. Shaffer and her supervisor Olsen felt this 
information would be beneficial to provide to their clients. This brochure is to be given to clients combined with  
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therapist education. The effectiveness of the client brochure is beyond the scope of this endeavor, but the hope is 
that it will better inform each client and include them more in the decision process as well.  
Effectiveness of meeting with Impedimed 
 
Over the duration of our project, we corresponded with Impedimed in order to learn more about the L-dex 
and insurance coverage. On April 10, 2017 we met with Fustgaard to discuss our research findings, review the 
content in our PowerPoint presentation, and gain more information regarding insurance covering BIS. The meeting  
went very well and based on Fustgaard’s feedback we felt that our research findings had more meaning because of 
its potential impact to benefit individuals with lymphedema. Fustgaard was very pleased with our research and 
presentation. She also had many Impedimed employees review our slideshow presentation, including the CEO, 
Richard Carreon who provided us with great constructive feedback. We had the opportunity to clarify and gain more 
insight on Medicare coverage and ensure that the information we were sharing from Impedimed was accurate and 
approved. Additionally, Fustgaard brought us great resources, including a recent study from 2016, which supports 
the conclusions we drew from our critical appraisal of the literature. This article was added to our CAT table to 
provide more evidence regarding effectiveness of BIS in clinical practice. Overall, meeting with Fustgaard was 
effective for all of us because it gave us an opportunity to share our findings and put our research more into a 
meaningful context. We gained perspective about how our critical appraisal has the potential to help make a 
difference in individuals needing lymphedema measurements. 
Effectiveness of Presentation to Sherri Olsen 
 
The presentation to Olsen on April 14, 2017 went very well. She expressed that she was pleased with our 
research findings, implications, and information regarding insurance coverage issues. She informed us that 
MultiCare’s oncology department is planning to initiate research of their own regarding the L-Dex. Olsen asked if 
we could send her our presentation and final paper to utilize for future reference. It was such a great experience to 
convey our findings to someone who is in the position to utilize them and make a difference in patients with 
lymphedema. Olsen confirmed that she currently is collaborating with Impedimed to discuss technological updates, 
insurance, and further research opportunities. Additionally, she confirmed that she understands the benefits of BIS 
and is supportive of using the L-Dex in clinical practice. Olsen made us feel that our review of the literature was 
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worthy and invaluable to those involved in lymphedema care. Overall, we felt that her response to our presentat ion 
indicated that our research analysis was effective and meaningful.  
Analysis of the Overall Process 
 
In September 2016, we chose to work with Shaffer, who is an occupational therapist and lymphedema 
specialist at MultiCare in Gig Harbor, WA. After meeting with her, we understood the focus of research she 
expected us to explore. The question we collaboratively constructed was not convoluted, rather direct and simple, 
which eliminated extensive research to first develop a research question. We were able to focus our time on finding 
a comprehensive amount of research on the lymphedema measurements in the literature. This caused the beginning 
of our process to be quite simple, but extensive. We felt inundated with a considerable number of articles to sift 
through with terms related to lymphedema that were unfamiliar to us. This required additional exploration to 
understand what several lymphedema terms meant and how they were implemented in practice. We watched videos, 
sought guidance from Shaffer, and read many additional articles to increase our comprehension. 
The factor that proved surprisingly difficult was ensuring that we had documented all the searches we had 
made, all the articles we kept, and all the duplicates we found. As a group of four individuals,  it proved even more 
difficult to ensure organization in our searches in order to not duplicate searches or miss important search avenues. 
Our chairperson along with our librarian liaison provided valuable insight to ensure higher likelihood for saturation  
of articles in an organized manner. After firmly developing our inclusion and exclusion criteria, it became clearer as 
to which articles we had to include and which must be excluded. Even with this criterion in place, there was room 
for differing interpretations among group members, which led to additional discussion to clarify each criterion. After 
developing our CAT table, we were constantly making decisions to guarantee a strong, evidence-based systematic 
review of the specific question we strived to answer. It was difficult for us to compare results for two reasons: 1) 
each article covered different pieces of psychometric data (although many were comparable) and 2) each 
measurement of lymphedema was not comparable as some measured limb mass while others measured volume, 
while others measured differences between lymph fluid and other fluids. During our writing of the summary of key 
findings and implications, we perceived that it was difficult to reduce redundancy with our information because our 
results were mostly unambiguous. 
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Once we finished our first draft of the paper, we met again with Shaffer on February 10, 2017. This 
meeting allowed us to verbalize our written conclusions and findings. We felt better prepared than we had 
anticipated, as we were still unsure if we were correctly understanding the plethora of new lymphedema terms along 
with all the psychometric data presented in the studies. When we explained the findings to Shaffer, they were well 
received and understood. The biggest challenge of this process was translating our newfound knowledge into 
practice. Shaffer’s expectation was to use this systematic review to present to her supervisors to convince insurance 
companies for further coverage of the L-Dex. Unfortunately, insurance policies are relatively well established and 
although policies oftentimes change, it is customarily a long and slow process. We received support for our research 
and our findings from our partnering clinician and Olsen. This support provides us with an optimistic outlook on 
how further research can support the development and implementation of the best lymphedema assessment  tools. 
Advocating for our conclusions combined with reaching the audience we intended demonstrated the importance of 
synthesis and knowledge translation. Shaffer, Olsen, and Fustgaard all concluded that this research would be helpful 
to present to insurance providers, but that more ongoing, rigorous evidence is needed to support the need for BIS. As 
new researchers, we felt empowered to know that our study is being utilized by seasoned practitioners.  
Recommendations for future research 
 
According to her responses to our questionnaire, Shaffer would like to see more longitudinal studies 
tracking client outcomes with tools that have the potential to detect lymphedema earlier than previously used tools. 
Fustgaard corroborated this by stating in her response to our outcomes questionnaire, “…payers desire…more 
evidence showing that subclinical detection has an impact on outcomes.” Based on information we found while 
researching monitoring lymphedema with assessments, we concur that more data on subclinical lymphedema is 
important. It is possible that the sensitivity of an assessment tool may help to prevent the development of clinical 
lymphedema with early detection (Bilir et al., 2012; Czerniec et al., 2010; Czerniec et al., 2009; Hidding et al ., 
2016). Both self-report (Czerniec et al., 2010) and BIS (Bilir et al., 2012; Czerniec et al., 2010; Czerniec et al., 2009; 
Hidding et al., 2016) were identified as sensitive assessments in our research. A thorough literature review on the 
subject of early detection of lymphedema should be conducted. Other research including single case studies and 
randomized control trials would also contribute to the information available on early detection. 
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New technology continues to be developed every day. The L-Dex is a relatively new technology when 
compared to water displacement and circumferential measurements to measure lymphedema. As we learned in 
speaking to Shaffer (personal communication, February 10, 2017) and Fustgaard (personal communication, April  
10, 2017), in order for a new treatment or assessment to be covered by insurance, it must go through different levels 
of billing codes. The code determines whether a particular insurance will cover none, part, or a ll of the cost of the 
coded item. Research as well as use in practice determines the billing code and whether insurance covers the 
assessment. This process of checks and balances takes time, so a new technology that is developed needs research to 
support its effectiveness it will be covered by insurance. It is important when considering lymphedema assessments 
to identify new technologies that may not be currently used in clinical practice or covered by insurance. Robotic 3D 
scanning was a topic of a few articles we located during our search (Chromy,2015; Öhberg & Holmner-Rocklöv, 
2014; Santin & Ward 2014 ). Research on this technology may expand. It is important that researchers and clinicians 
remain aware and open to the possibility of new and possibly better instruments to measure lymphedema. 
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 LYMPHEDEMA 
 ASSESSMENTS 
 L-Dex Device (Bioimpedance) 
 versus 
 Circumferential  Measurements 
 
 LYMPHEDEMA REHAB CLINICS 
 
MultiCare Covington Clinic 
17700 SE 272nd St- 
Covington, WA 98042 
p 253-372-7030 
f 253-372-7032 
 
MultiCare Gig Harbor Medical Park 
4545 Pt- Fosdick Dr- NW 
Gig Harbor, WA 98335 
p 253-530-8122 
f 253-530-8126 
 
MultiCare Good Samaritan Hospital 
401 15th Ave SE 
Puyallup, WA 98371 
p 253-697-7900 
f 253-697-5180 
 
MultiCare Regional Cancer Center - 
Tacoma General Hospital 
315 Martin Luther King Jr- Way 
Tacoma, WA 98405 
p 253-403-1040 
f 253-403-4873 
 
FOR MORE 
INFORMATION 
 
please speak with your 
occupational or physical 
therapist at MultiCare or 
visit the following websites: 
 
● Impedimed.com 
 
● multicare.org/rehabilitation- 
services-lymphedema/ 
 
Sources: 
 
● Impedimed.com 
 
● soundideas.pugetsound.edu/student_pubs/ 
Search Ramolete, Wyatt, Enyeart & Foxlee 
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CIRCUMFERENTIAL 
MEASUREMENTS 
Definition: the use of a tape to measure the 
circumference of a limb at specific locations. 
These measurements are used by your 
therapist to calculate limb volume and to fit 
compression garments 
 
 
 Pros: 
 
● Well-known 
● Standards are established 
● Easy to use 
 
 
 Cons: 
 
● Cannot detect small changes in fluid 
● Cannot differentiate between 
different forms of edema 
 
● Training is required 
 
● Takes at least 15 minutes to administer 
● Should be retested at same time of 
day with same tool and same 
therapist 
 
 
 
 
 
 
 
 
 
 
 
Impedimed.com 
 
L-DEX DEVICE 
Definition: this device measures the 
electrical impedance of biological tissue in 
response to an applied alternating current. 
In the presence of lymphedema, the 
applied current will travel predominantly 
through the accumulation of lymphatic 
fluids. 
 
 Pros: 
 
● Early detection of lymphedema 
● Can detect differences between 
non- lymphatic fluids and lymphatic 
fluids 
 
● Can detect small differences in 
the amount of lymphatic fluid 
 
● Reliable and valid when compared with 
gold standards. 
 
● Time-efficient (takes less than 
5 minutes to administer) 
 
● Easy to use 
 Cons: 
 
● MultiCare charges $70 for this, 
unless your insurance covers the 
cost 
 
● Cannot be compared with other 
assessments (for validity, if the 
first assessment was done using 
L-Dex, subsequent re-assessments 
should be done with L-Dex as well) 
Impedimed.com 
Why should I care which 
lymphedema assessments 
my therapist uses? 
● It helps to ensure that you are 
getting the treatment that is 
conducive to your needs. 
● Because of varied accuracy of 
measures, you may be able to 
treat symptoms of lymphedema 
earlier. 
● It impacts the amount of time you 
have to spend in a clinic to be 
treated 
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Appendix B 
 
Lymphedema In-Service Presentation 
 
 
 
 
 
 
 
 
Critically Appraised Topic:  
 
Comparisons of Lymphedema 
Assessments   
 
Jessica Enyeart, Cullyn Foxlee, Divina Ramolete, Connie Wyatt  
Purpose 
To review and critique the research comparing lymphedema assessments in  
order to determine if BIS truly is the best instrument used in practice, or if 
other assessments are shown to be better.   
To utilize the evidence in such a way that the L-Dex may have more potential in  
becoming a covered lymphedema assessment by federal insurance 
companies.  
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Research Question 
How do bioimpedance spectroscopy (BIS), 
circumferential measurements (CM), and 
perometry (OP) compare to one another based on 
reliability, validity, cost, and time-eﬃciency for 
measuring unilateral lymphedema (LE)? 
 
 
 
THE RESEARCH 
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Overview of the Research Criteria 
Inclusion Criteria:  
 
LE of arms and legs, secondary LE, unilateral lymphedema, BIS, CM, perometry (including 
infrared optoelectronic volumetry/perometry) and studies done anywhere in the world. 
Exclusion Criteria  
 
Primary LE, non-human subjects, self-assessment, children, articles older than 1990, head/ 
neck LE, studies solely measuring early diagnosis or detection of breast cancer-related 
lymphedema (BCRL), water volumetric measurements (if not compared to CM, BIS or 
perometry), and tonometry if not within a systematic review/meta-analysis. 
 
OUR FINDINGS 
●  1504 articles found 
 
●  1400 articles rejected 
●  79 articles were duplicates 
 
●  29 total articles reviewed and placed into our critical 
appraisal of topics table 
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HISTORY OF LYMPHEDEMA GOLD STANDARD ASSESSMENTS 
 
CM v. BIS v. OP 
Circumferential measurements (CM), water displacement (WD), and bioimpedance (BIS) are highly 
recommended due to their reliable and valid psychometric properties and clinical utility (Perdomo et al., 
2014). 
 
WD and CM, regarded as the former gold standards to measure lymphedema were commonly compared. 
 
WD and CM (as the historical gold standards) provided a comparison in the literature to assist in determining 
the psychometric properties of OP and BIS. 
 
CM and perometry (OP) demonstrated high inter-rater reliability and intra-rater reliability when compared to WD 
which did not have as high inter-rater and intra-rater reliability (Deltombe et al., 2007). 
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CM v. BIS v. OP (continued) 
Strong correlations found between CM and OP; moderate/strong correlations between CM and BIS 
methods. (Ridner et al., 2007 and Mayrovitz et al., 2000) 
 
BIS and OP demonstrated relatively poor limits of agreement due to having diﬀerent units of 
measurement. (Ward et al. 2009a) 
 
OP measures total arm volume 
 
BIS speciﬁcally measures extracellular ﬂuid 
 
BIS can detect localized lymphedema more readily than OP. (Czerniec, et al., 2009) 
Patients assessed with CM had sig. higher incidence rates of clinical LE (36.4%) compared to BIS (4.4%) 
(Soran et al., 2014) 
BIS Pros 
+ Reliable: High Inter-rater Reliability (Jain et al., 2010) 
 
+ Valid for early detectiuon (Shah et al., 2013) and measuring leg volume changes (Moseley et al., 
2002) 
 
+ More Time-Eﬃ cient (Ridner et al., 2007) 
 
+ CM: 25 min 
 
+ BIS via Impedimed Device: 6 min 
 
+ Economically Beneﬁ cial (Bilir et al., 2012) + 
+ 
Client & Clinician Preferred (Ward, 
2006) 
Clinical utility & Feasibility (Laidley & Anglin, 
2016) 
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BIS Pros (continued) 
+ Level of sensitivity: Ability to detect lymphedema earlier than other assessment methods 
(Bilir et al., 2012; Czerniec et al., 2010; Czerniec et al. 2009; Hidding et al., 2016) 
 
+ Ideal measurement for early stages of lymphedema (Shah et al. 2013; Bundred et al. 2015) 
 
+ Ability to diagnose subclinical LE (Soran et al., 2014; Laidley & Anglin, 2016) 
 
+ Eﬀective for later stages (Bundred et al., 2015) 
 
+ Eﬀective tool for diagnosis of well-established BCRL (Seward et al., 2016) 
+ Capacity to discriminate between diﬀering ﬂuids within the limbs: ECF and other ﬂuids 
(Czerniec et al., 2009) 
+ Overall literature suggested that BIS may be the most suitable assessment in comparison 
BIS Cons 
Seward et al. (2016) claimed that there is not enough evidence to conclude that BIS detects 
breast cancer related lymphedema earlier than other measurement techniques 
Contraindicated for clients who are pregnant or have pacemakers 
L-Dex machine does not measure UE lymphedema in men 
Expensive: Medicare in the Noridian Region JF (our region) does not cover costs 
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IMPLICATIONS 
Implications for Patients  w/Lymphedema 
BIS would be the preferred assessment to measure preoperative baselines because its high sensitivity allows for 
earlier detection of lymphedema (Bundred et al., 2015; Shah et al., 2013) 
BIS has the ability to carefully monitor LE, diagnose subclinical LE, and initiate early intervention, thus reducing the 
incidence rates of clinical LE (Soran et al., 2014) 
Early diagnosis of lymphedema via BIS has shown potential to lead to a better prognosis because treatment can be 
started sooner rather than later, resulting in overall lower total treatment costs (Bilir et al., 2012) 
Evidence shows that treatment of lymphedema implemented earlier may prevent chronic lymphedema (Bundred et al., 
2015) 
BIS is faster: provides ease of scheduling for consumers and more $me to treat in session (Ridner et al., 2007) 
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Implications for Occupational  Therapy 
OTs must use discretion and decide if implementation of these measurement tools are integral to the 
ethics of their practice and the needs of their client population. 
 
Considering the pros of BIS found in our research may: 
 
Allow lymphedema specialists (OTs & PTs) to be more certain that they are using valid and reliable 
assessments in order to provide optimal care for clients. 
 
Impact clinical reasoning to select an assessment that is in the best interests of their clientele. 
 
Focus sessions more on treating lymphedema and meeting client needs rather than spending a majority 
of the time assessing lymphedema. 
 
Lead to early detection 
A key factor in determining between acute and chronic lymphedema (Bundred et al., 2015). 
Implications for Researchers 
Many studies noted that lymphedema is not well deﬁned 
 
Diﬃcult to compare among studies 
 
Limited blinded and RCT studies (Hidding et al, 2012; Impedimed correspondence) 
 
However, in an example when blinding was partially utilized, there was potential for inaccurate reliability 
results (Sander et al., 2002). 
BIS via L-Dex measures unilateral lymphedema only 
 
Limited accuracy for bilateral lymphedema (Warren et al., 2007). 
Studies with more thorough speciﬁcity and sensitivity to deﬁne more precisely appropriate cut oﬀ 
values for leg lymphedema (York et al., 2009). 
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Implications for Evidence  Researchers 
● Robotic 3D scanning found among literature 
○ A new technology that may be eﬀective in lymphedema measurement. 
 
● Future research should be conducted on early detection and diagnosis of 
lymphedema as well as self-report and robotic measurements. 
CURRENT PROBLEM: Insurance  Coverage 
Currently, Heidi Shaﬀer is having issues with federal insurance companies such 
as Medicare, Medicaid, and Tricare NOT covering use of the L-Dex. 
According to Impedimed’s insurance representative, Washington is located in 
the JF Noridian Medicare region, which does not provide consistent 
coverage of BIS measures. 
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Retrieved via 
Impedimed  Insurance Representative 
WHY? 
Generally we see Medicare nationally covering BIS. Unfortunately the Medicare 
Administrative Contractor (MAC) of our Noridian region covers BIS sporadically. 
 
Impedimed plans to continue building an evidence base, supporting positive clinical outcomes associated 
with their technology. 
New Technology: BIS received a CPT-1 code in Jan. 2015 
This calls for MORE studies with stronger rigor 
 
Random Control Trials 
Reliable and Clear Methods 
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Recommendations to Acquire Medicare Coverage 
The regional MAC needs to see compelling clinical evidence 
relating to positive health outcomes. 
HOW CAN WE DO THAT? 
More research 
Impedimed is currently conducting RCTs and collaborating with national clinici 
to analyze their client outcomes. 
Target private insurance companies to advocate for BIS use 
Raise community awareness of the benefits of BIS for lymphedema 
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Appendix C 
Outcome Measures 
 
 
Questionnaire – HEIDI SHAFFER 
 
Lymphedema measurements: Which is most valuable for best practice? 
 
Thank you for meeting with us. It would enhance our project if you would answer these questions based on the 
information we discussed. By filling out this form you acknowledge that we will use the information from these 
answers in our project and it will not be anonymous. 
 
 Did you learn anything new from the information we presented? If, yes, what was the new information? 
 
Yes, I learned that many states do have coverage for the LDex measurement tool and I learned some ways 
to assist with our state coverage. I learned more about the accuracy of the LDex measurement tool.  
 
 Is there anything you feel we missed or did not consider? 
 
I think you all did a great job of assessing the tools we currently use as well as some other tools we use 
less. I feel confident that the L-Dex is an excellent tool to use. I also feel that in the future this tool will be 
more readily covered by insurance. 
 
 What would you like to see considered in future research? 
 
I feel it’s good to stay current with new measurement tools that might be on the horizon. Insurance policies 
and coverage consistently change, so it would be good to stay abreast to those changes. It would be great to 
see longitudinal studies using various tools and see how patient outcomes are improved with early 
lymphedema detection. 
 
 Will the information presented change how you advocate for coverage for lymphedema measurements? 
 
Absolutely. It’s great to know that we can advocate for coverage and change with the insurance companies 
and it takes studies like this to make those changes. 
 Do you have any further thoughts after our discussion? 
 
My thoughts are for early detection and advocacy for measurement tools to prevent lymphedema. The tools 
can also be used to show outcomes with therapy. For example, true measurements for before therapy and 
improvement after. Excellent tool for insurance companies and demonstrating positive outcomes with this 
population. 
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Questionnaire – SHERRI OLSEN 
 
Lymphedema measurements: Which is most valuable for best practice? 
 
Thank you for meeting with us. It would enhance our project if you would answer these questions based on the 
information we discussed. By filling out this form you acknowledge that we will use the information from these 
answers in our project and it will not be anonymous. 
 
 Did you learn anything new from the information we presented? If, yes, what was the new information? 
 
No 
 
 Is there anything you feel we missed or did not consider? 
 
No 
 
 What would you like to see considered in future research? 
 
Nothing that I can think of 
 
 Will the information presented change how you advocate for coverage for lymphedema measurements? 
 
No 
 Do you have any further thoughts after our discussion? 
 
Thank you for all the updated information and work you did to identify payer information.  
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Questionnaire – MAREN FUSTGAARD 
 
Lymphedema measurements: Which is most valuable for best practice? 
 
 
Thank you for meeting with us. It would enhance our project if you would answer these questions based on the 
information we discussed. By filling out this form you acknowledge that we will use the information from these 
answers in our project and it will not be anonymous. 
 
 Did you learn anything new from the information we presented? If, yes, what was the new information? 
 
Yes, I learned how the research team will be rolling out their results to have an impact on regional 
providers 
 
 Is there anything you feel we missed or did not consider? 
 
As we discussed, I think it’s helpful to make it clear that Medicare generally pays for the product 
nationally, but individual regions don’t tend to pay, as opposed to making the blanket statement that 
Medicare isn’t covering. The changes to the slides we discussed do a good job clarifying this  
 
 What would you like to see considered in future research? 
 
One of the biggest barriers we find with commercial payers I desire for more evidence showing that 
subclinical detection has an impact on outcomes 
 
 Will the information presented change how you advocate for coverage for lymphedema measurements? 
 
I like the idea of working with researchers such as your team to approach regional clinics, so going forward  
 
 Do you have any further thoughts after our discussion? 
 
Thanks for taking the time to meet! 
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Suggested Brochure Outcomes Questions 
 
 
The purpose of the following questions is to facilitate gathering information on the use of the informational 
brochures created and distributed. These questions are intended to be answered three months, six months, and then a 
year after brochures were initially provided by research team. We encourage clinicians to create their own 
monitoring outcomes tools. 
 
1. How many brochures were taken by patients in the first (3 month, 6 month, 1 year) period? 
 
 
2. Where were brochures placed? 
 
 
3. From what location were the most brochures taken? 
 
 
4. Did patients ask any clarifying questions on the brochures? If so, what were they? 
 
 
5. Was there a change in the number of people who chose CM and/or BIS after brochures were made 
available? 
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O N I YE R S ITY of 
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School of Occupational Therapy and Physical Therapy 
1500 N. Warner CMB #1070 
Tacoma, WA 98416-1070 
 
Occupational  Therapy  Program On-Site Clinic 
 
Consent for ANY and ALL Images 
PbotograpbyNideograpby/Phone 
 
 
 
 
0 
Faculty/Studlnt Therap\st 
Name  _ 
 
Position  5-, Parent/Guargian Name  _ 
 
I hereby give permiss, • 
Id/ward \d) 
to appear as a subject in an image, such as videotapes, photographs, and/or smartphones, etc. while at the 
School of Occupational Therapy  and Physical Therapy of the University  of Puget  Sound. 
The purpose of the images has been explained to me. I also understand that the images will be 
under the control of the University of Puget Sound Faculty. In addition, I understand that this consent is 
specifically  for:  (CIRCLE OR WRITE  IN ALL THAT APPLY) 
 
 
c inic/classroom/research  study/project) 
 
I understand that first names may be used in these images, with which there is no way to try to 
conceal the identity of the subjects. I also understand that I may cancel this consent by written notice and  
that this cancellation is without penalty and will in no way affect my future care and services, or academic 
standing.     I have had the opportunity to ask question to obtain the kind of information I need to make such 
a decisio \ A • 
. ill ,    · L{-5 it' 
Signature of Subject (if applicable Date 
 
 
Signature of Parent or Guardian (if applicable) Date 
 
 
'Signature of Subjct Advocate (if applicable) 
'"'If        •• 
Date 
 
 
  
 
 
 
 
 
 
Revised 11/04/14 SDD 
Phone: 253-879-3281 option#1; Fax: 253-879-2933; Email:otclinic@pugetsound.edu 
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CONS ENT FOR M 
 
4/10/17 
 
Dear lmpedimed, 
 
We (UPS OT636 Research Group) have permission to use photos and insurance information 
from lmpedimed resources. We will ensure that all materials we use from your company is 
authentic and cited appropriately. 
 
 
 
Thank you, 
 
 
Divina Ramolete  ;/} cfj, 0Ln 
 
 
Cullyn Foxlee      
 
Connie Wyatt  _C_it_L·Jr_#  
tJ l//10/ 2017 
 
0_,1/1--0/_I '?- __ 
 
Jessica Enyeart  -'f/ro/n 
 
 
 
 
 
 
Date:  u/ ..., 0 ... f t 
 
 
 
Signature: Date:  _ 
 
  
  
 
Permission for Scholarly Use of Thesis 
 
To properly administer the Research Repository and preserve the contents for future use, the University of Puget 
Sound requires certain permissions from the author(s) or copyright owner. By accepting this license, I still retain 
copyright to my work. I do not give up the right to submit the work to publishers or other repositories. By accepting 
this license, I grant to the University of Puget Sound the non-exclusive right to reproduce, translate (as defined below), 
and/or distribute my submission (including the abstract) worldwide, in any format or medium for non-commercial, 
academic purposes only. The University of Puget Sound will clearly identify my name(s) as the author(s) or owner(s) 
of the submission, including a statement of my copyright, and will not make any alteration, other than as allowed by 
this license, to my submission. I agree that the University of Puget Sound may, without changing the content, translate 
the submission to any medium or format and keep more than one copy for the purposes of security, back up and 
preservation. I also agree that authorized readers of my work have the right to use it for non-commercial, academic 
purposes as defined by the "fair use" doctrine of U.S. copyright law, so long as all attributions and copyright 
statements are retained. If the submission contains material for which I do not hold copyright and that exceeds fair use, 
I represent that I have obtained the unrestricted permission of the copyright owner to grant the University of Puget 
Sound the rights required by this license, and that such third-party owned material is clearly identified and 
acknowledged within the text or content of the submission. I further understand that, if I submit my project for 
publication and the publisher requires the transfer of copyright privileges, the University of Puget Sound will 
relinquish copyright, and remove the project from its website if required by the publisher. 
 
 
 
Name:  Jessica Enyeart Date:  5/12/17  
 
 
 
Jessica Enyeart, OTS 
 
 
Name:  Cullyn Foxlee Date:  5/12/17  
 
 
 
Cullyn Foxlee, OTS 
 
 
Name:  Divina Ramolete Date:  5/12/17  
 
 
 
Divina Ramolete, OTS 
 
 
Name:  Connie Colleen Wyatt Date:  5/12/17  
 
 
 
Connie Colleen Wyatt, OTS 
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